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Cardiac arrhythmias affects millions of Americans and can lead to sudden cardiac death, 
accounting for more than 300,000 deaths annually. Despite the vast knowledge available for 
cardiac disease and associated arrhythmias, very few effective therapies exist. Current 
interventions include cardioverter defibrillators and antiarrhythmic drugs targeting ion channels or 
the β-adrenergic pathway. In most acquired and inherited arrhythmias, molecular signaling 
pathways are perturbed. However, little is known about the underlying mechanism of how these 
signaling pathways regulate cardiac electrophysiology. Therefore, a better understanding of major 
signaling pathways governing cardiac development or dysregulated in cardiac disease could lead 
to novel therapeutics for the treatment of arrhythmias. In my thesis dissertation, I show that the 
Wnt signaling pathway directly regulates genes relevant for cardiac electrophysiology in both the 
embryonic and adult murine heart. Additionally, I found that pharmacologic inhibition of the 
glycogen synthase kinase 3 pathway in the adult human heart results in electrophysiological 
changes that could contribute to an arrhythmogenic substrate.  
In the first part of my thesis, I show that developmental perturbation of Wnt signaling leads to 
chamber-specific transcriptional regulation of genes important in cardiac conduction that persists 
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into adulthood. Transcriptional profiling of right versus left ventricles in mice deficient in Wnt 
transcriptional activity reveals global chamber differences, including genes regulating cardiac 
electrophysiology such as Gja1 and Scn5a. In addition, the transcriptional repressor Hey2, a gene 
associated with Brugada syndrome, is a direct target of Wnt signaling in the right ventricle only. 
These transcriptional changes lead to perturbed right ventricular cardiac conduction and cellular 
excitability. Ex vivo and in vivo stimulation of the right ventricle is sufficient to induce ventricular 
tachycardia in Wnt transcriptionally inactive hearts, while left ventricular stimulation has no effect. 
These data show that embryonic perturbation of Wnt signaling in cardiomyocytes leads to right 
ventricular arrhythmia susceptibility in the adult heart through chamber-specific regulation of 
genes regulating cellular electrophysiology. 
In the second part of my thesis, I use a human cardiac slice culture platform to show that inhibition 
of glycogen synthase kinase 3 (GSK-3) pathway alters the cardiac electrical substrate. Glycogen 
synthase kinase 3 (GSK-3) is a multifunctional regulatory kinase that has emerged as a potential 
therapeutic target for several diseases, including cancer, diabetes, and bipolar disorder. In the heart, 
dysregulation of GSK-3 has been implicated in pathological conditions such as cardiac 
hypertrophy, ischemic injury, and heart failure, which are often accompanied by arrhythmias. 
Despite growing evidence that dysregulation of GSK-3 is associated with arrhythmias, the precise 
role for GSK-3 regulation of human cardiac electrophysiology remains poorly defined. Human 
cardiac slices cultured with the GSK-3 inhibitor SB216763 showed reduced conduction velocity 
at 3 and 24 hours in culture compared to vehicle controls. Action potential measurements revealed 
decreased excitability in GSK-3 treated slices, as measured by decreased dVm/dtmax. Computational 
simulations demonstrated that decreased sodium channel conductance and tissue conductivity are 
plausible causes for observed reduction in conduction velocity and dVm/dtmax. β-catenin, a target 
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of GSK-3 and the transcriptional effector of Wnt signaling, increased within cardiomyocyte nuclei 
as expected. However, transcription of Wnt/β-catenin target genes and SCN5A were unchanged, 
while NaV1.5 protein, the major cardiac sodium channel subunit, decreased after 3 hours in culture 
with SB216763. This suggests that acute GSK-3 inhibition-mediated regulation of cardiac 
electrophysiology can occur in part through post-transcriptional mechanisms, and that therapeutic 
strategies targeting the GSK-3 pathway may be associated with an increase in adverse 
cardiovascular effects. 
I demonstrate here that two inter-related signaling pathways, Wnt and GSK-3, regulate cardiac 
electrophysiology through modulation of ion channels regulating cardiac conduction via 
transcriptional and post-transcriptional mechanisms. In addition to the contribution to basic 
research through advancing our overall understanding of molecular signaling pathways in cardiac 
conduction and arrhythmias, these results may provide insight for translational pre-clinical 
research to aid in the development of novel antiarrhythmic drugs.
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Chapter 1: Introduction 
Heart disease is the prevailing chronic disease in the United States and accounts for the highest 
percent of deaths1. Among the 647,000 American deaths from heart disease each year, more than 
340,000 are sudden cardiac deaths (SCD), which are primarily caused by ventricular arrhythmias1. 
Arrhythmias are conditions in which the electrical activity of the heart becomes fast, slow, or 
irregular, increasing risk for fibrillation and culminating in SCD. Ventricular arrhythmias are 
caused by a combination of structural heart disease, genetic factors, and perturbation of various 
signaling pathways2. Over the past 50 years, the mechanism of arrhythmogenesis by altered 
structure or ionic currents have been well characterized. However, the molecular mechanisms 
involving genetics and signaling pathways underlying arrhythmogenesis are only beginning to 
become established areas of study. Furthermore, because the current knowledge base is biased 
towards tissue and organ level structural mechanisms such as fibrosis, very few effective 
therapeutics targeting the non-structural facets underlying cardiac arrhythmias exist. The current 
standard for treatment of ventricular fibrillation to prevent sudden cardiac death is the implantable 
cardioverter defibrillator, which most patients suffering from arrhythmias do not qualify for and 
has disadvantages such as high costs and increased morbidity3. On the other hand, antiarrhythmic 
drugs targeting ion channels are often ineffective and, due in part to their non-specificity, can 
paradoxically be proarrhythmic4. These traditional antiarrhythmic drugs target a single molecular 
target, such as sodium or potassium channels, which can lead to unintended electrophysiological 
consequences in a complex multicellular system such as the heart. Currently, biological 
antiarrhythmic therapies targeting signaling pathways that regulate electrophysiology directly or 
indirectly are rare. In many congenital and acquired cardiac arrhythmias, certain signaling pathway 
activities are aberrantly activated: for example, the Hippo pathway in arrhythmogenic 
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cardiomyopathy5, and the MAP kinase pathway in atrial fibrillation and heart failure6. These same 
pathways are quiescent or minimally active in the healthy adult heart. Therefore, the approach to 
target signaling pathways known to regulate electrophysiology for treatment of arrhythmias may 
be safer and more effective. One example of this is the use of β-adrenergic receptor blockers, which 
does not directly affect ion channels, for treatment of tachycardia by reducing hyperinnervation of 
cardiomyocytes by sympathetic nerves7. However, the paradigm of signaling pathways regulating 
cellular electrophysiology is only emerging and little is known outside of the β-adrenergic pathway 
as an antiarrhythmic target. Therefore, further studies into how signaling pathways can regulate 
both cardiac structure and electrophysiology can provide insight into cardiac development, disease, 
arrhythmogenesis, and lead to novel therapeutics. 
1.1 Cardiac development  
Vertebrate heart development occurs in multiple phases, including specification of myocardial and 
endocardial precursors to form bilateral heart fields within the mesoderm, merging of the heart 
fields to form the linear heart tube, cardiac looping, chamber formation, septation, formation of 
the cardiac valves, and maturation8, 9.  
Specification of precursor cells occurs in the mesodermal layer. Cardiac progenitors migrate 
through the anterior region of the primitive streak and forms two cardiogenic regions that 
eventually fuse to become the cardiac crescent (Figure 1.1.1A, B). The cardiac crescent is 
composed of two distinct cell populations, namely the first heart field (FHF) and the second heart 
field (SHF), defined by distinct marker genes and different gradients of commonly expressed 
genes. The cells of the FHF eventually forms the endocardium and myocardium, maturing into the 
left ventricle (LV), half of the septum, parts of the atria, and the atrioventricular canal (AVC). 
Marker genes for the FHF include GATA and Tbx20 transcriptional factors10. The SHF eventually 
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forms the right ventricle (RV), RV outflow tract (RVOT), and parts of the atria. Marker genes for 
the SHF include Islet1 and Mef2c transcriptional factors.    
 
Figure 1.1.1. Multistage development of the heart. Figure adapted from Brade et al. 11. 
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The heart forming fields then move towards the midline of the embryo and merge to become a 
linear heart tube, which eventually becomes the ventricles (Figure 1.1.1C). The FHF and SHF 
begins to merge during cardiac looping, forming the atria at the end of the process (Figure 1.1.1D). 
Once cardiac looping has completed, the primitive chambers of the heart can be identified, with 
each chamber expressing a different collection of genes for further development and maturation12. 
Between the endocardium and the myocardium of the linear heart tube is a layer of extracellular 
matrix called the cardiac jelly (Figure 1.1.1D). During cardiac looping and chamber formation, 
extracardiac progenitors migrate into the cardiac jelly in the AVC to form the endocardial cushion. 
The endocardial cushion then remodels to become cardiac valves (Figure 1.1.1F). At the same 
time, the AVC goes through septation, regression, and eventual formation of parts of the cardiac 
conduction system (Figure 1.1.1F).    
1.2 The Wnt signaling pathway 
Development of the heart requires the proper orchestration of multiple molecular signaling 
pathways. My thesis is focused on the Wnt signaling pathway, which has been implicated in 
cardiac development, congenital heart disease, and adult cardiomyopathies. The following sections 
summarize these findings and establishes the background for my hypothesis of Wnt-mediated 
regulation of cardiac electrophysiology.  
The Wnt signaling pathway is a highly evolutionarily conserved signal transduction cascade 
involved in a myriad of biological processes throughout development and adulthood13. In 1984, 
the int-1 gene was discovered near integration sites for mouse mammary tumor virus and found to 
be overexpressed in the tumors14. Subsequently, the Wingless gene was found to be a homologue 
of int-1 in drosophila, with loss-of-function mutations at Wingless leading to developmental 
defects such as loss of the wings15, 16. Therefore, the int-1 and Wingless genes became the one of 
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the first genes to be both required in development and activated in disease. The name Wnt arose 
from the combination of Wingless and int-1, and a family of genes later identified to be coupled in 
signaling became the Wnt pathway.  
Over the last 30 years, the Wnt signaling pathway has been an active area of research in 
mammalian development and disease, with the discovery of many signaling components and 
mechanisms. The first Wnt genes described, int-1 and Wingless, code for secreted protein ligands 
that initiates the signaling cascade17. To date, 19 orthologs of Wnt genes have been discovered, 
each coding for a specific protein ligand with distinct downstream functions18. In general, Wnt 
protein-ligands bind extracellularly to a family of 10 transmembrane G protein-coupled Frizzled 
receptors19. Different Wnt signaling processes can be activated depending on the cell type, Wnt 
ligand, and Frizzled receptor. The two main pathways that involve Wnt proteins binding to 
Frizzled receptors are the canonical β-catenin-dependent and the noncanonical β-catenin-
independent pathways20. In many cell types of mature tissues, Wnt ligands are not bound to 
Frizzled receptors. In this homeostatic condition, cytosolic β-catenin is phosphorylated by a 
destruction complex, which targets it for ubiquitination and degradation by proteasomes (Figure 
1.2.1)21. The destruction complex includes the proteins Axin, adenomatous polyposis coli (APC), 
casein kinase (CK1), glycogen synthase kinase (GSK-3), and β-catenin. Sequential 
phosphorylation of β-catenin occurs at Ser45 by CK1α, then Ser33, Ser37, and Thr41 by GSK-
3β22, 23. Phosphorylated β-catenin is ubiquitinated by E3-ligase β-transducin repeat-containing 
protein (BTrCP) and subsequently degraded by proteasomes. In the canonical Wnt pathway, upon 
binding of a Wnt ligand to Frizzled receptors, the transmembrane co-receptor low-density 
lipoprotein receptor-related protein (LRP5/6) undergoes a conformational change to expose a 
cytosolic motif which recruits Axin away from the destruction complex, destabilizing it and 
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preventing further β-catenin degradation24. Cytosolic β-catenin can then accumulate and 
eventually translocate to the nucleus, where it displaces transcriptional co-repressors histone 
deacetylase (HDAC) and Groucho, binds to transcription factor T-cell factor/lymphoid enhancer 
factor (TCF/Lef), and acts as a transcriptional co-activator to initiate transcription of Wnt-
responsive genes13. Many genes are dynamically regulated by canonical Wnt signaling, in a 
complex manner that depends on temporal, spatial, and cell-type specifications. 
 
Figure 1.2.1. The canonical Wnt signaling pathway. A. When no Wnt ligand is present, the 
canonical Wnt pathway is off. β-catenin is phosphorylated by a destruction complex and targeted 
for ubiquitination and degradation. B. In the presence of a Wnt ligand, the destruction complex is 
disrupted from phosphorylating β-catenin, allowing it to accumulate and translocate to the nucleus, 
where it binds to TCF/LEF and recruit coactivators to activate Wnt target genes. Figure adapted 




Aside from canonical β-catenin-dependent signaling, the Wnt pathway also encompasses several 
β-catenin-independent signaling processes. One major noncanonical Wnt signaling pathway is the 
Wnt/calcium pathway, which involves interactions between Frizzled proteins and heterotrimeric 
G-proteins to regulate intracellular calcium levels, calcium/calmodulin-dependent kinase II 
(CamKII), calcineurin, and calcium sensitive enzymes such as protein kinase C (PKC) 26. Another 
noncanonical Wnt signaling pathway is the planar cell polarity pathway (PCP), which regulates 
cellular orientation and shape. During development, an essential mechanism for cellular 
proliferation and differentiation is signaling transduction that allows cells to grow and migrate in 
the correct orientation. In drosophila, PCP signaling is involved in the polarization of bristles and 
wing hairs27, while in vertebrates, PCP regulates body axis elongation during gastrulation, sensory 
hair cell orientation, and directed migration28.  
1.3 Wnt signaling in cardiac development 
The heart is the first organ formed during embryogenesis, and both canonical Wnt/β-catenin and 
non-canonical/non-β-catenin Wnt signaling events are required for proper cardiovascular 
development28. Wnt proteins regulate cell proliferation, migration, and differentiation during 
cardiac embryonic development. However, the specific effects of Wnt signaling during 
development are both time and concentration dependent; its role at each stage of development: 
cardiac progenitor specification, heart tube formation, cardiac looping, chamber formation, and 
maturation is vastly complex and distinct. The role of Wnt signaling in early stages of cardiac 
development, during myocardial specification and cardiac morphogenesis, is well characterized. 
Multiple Wnt ligands and receptors are expressed in a spatially and temporally regulated manner. 
For example, during gastrulation, Wnt2 and Wnt11 are initially co-expressed within the murine 
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heart tube until eventually Wnt2 expression becomes restricted to the pericardium29. Cardiac 
progenitor cells derive from the mesoderm, which requires Wnt/β-catenin signaling; the mesoderm 
does not form in mice lacking β-catenin, and loss of Wnt3a results in decreased mesoderm marker 
gene expression30. However, while mesodermal formation require Wnt/β-catenin signaling, 
cardiac differentiation seemingly cannot occur without its inhibition. Studies in chicken and 
Xenopus embryos show that inhibition of canonical Wnt/β-catenin signaling leads to myocardial 
specification; inhibition of the pathway by Wnt inhibitors and deletion of β-catenin both result in 
ectopic cardiomyocyte formation, while overexpression of Wnt ligands blocks cardiogenesis31, 32. 
These contrasting results are reconciled by findings showing that the effects of Wnt signaling 
during stages of early cardiac development is both time and concentration dependent33, 34. Other 
studies have shown that non-canonical Wnt signaling is also required in early cardiac development. 
In mouse, Xenopus and zebrafish, Wnt11 promotes myocardial marker gene expression and is 
linked to the activation of a non-canonical Wnt signaling pathway35. Loss of Wnt11 results in 
defects in linear heart tube formation in Xenopus and defective fusion of heart-forming fields in 
zebrafish, while gain-of-function studies show increased number of progenitor cells with 
myocardial marker gene expression in both mouse and human36, 37. Therefore, during early 
development, canonical Wnt signaling is required for embryogenesis, giving rise to a cardiac 
progenitor population from the mesoderm. During cardiac differentiation and morphogenesis, 
concurrent inhibition of canonical Wnt signaling and activation of non-canonical Wnt signaling is 
required for proper cardiogenesis. 
The role of Wnt signaling in later development, during chamber formation and maturation, is more 
complex and multifaceted. Wnt signaling is implicated in formation of the heart valves, outflow 
tracts, and the cardiac conduction system.  Cardiac neural crest cells, a population of extracardiac 
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progenitors, migrate to the embryonic outflow tract during heart looping and chamber formation. 
Multiple Wnt ligands are expressed in these cells, and perturbation of Wnt signaling through loss 
of these ligands or β-catenin results in congenital heart defects such as outflow hypoplasia and 
abnormal septation38. Valve formation is also a process related to outflow tract development and 
septation. Cells from the atrioventricular canal (AVC) undergo epithelial-mesenchymal transition, 
migrate into the space between endocardium and myocardium to form the cardiac cushions, which 
forms the eventual tricuspid and mitral valves. Wnt/β-catenin signaling is required and tightly 
regulated in cardiac cushion development; excessive Wnt/β-catenin signaling results in an 
abnormally expanded cushion and AVC while inhibition of the pathway leads to reduced cushion 
formation39, 40. Proper patterning of the AVC is not only important for chamber alignment and 
valve formation, but also for the development of the AV node, a part of the cardiac conduction 
system that allows for the delay of electrical impulses between atria and ventricles. During late 
development, the AVC myocardium regresses until the AV node remains as the only myocardial 
connection between the atria and ventricles41, and perturbations to AVC maturation can lead to 
arrhythmias such as AV nodal block, AV reentrant arrhythmias, and ventricular preexcitation. In 
addition to the AV node, Wnt has been implicated in the regulation of other pacemaker 
cardiomyocytes, from the sinoatrial (SA) node. Previous mouse studies have shown that canonical 
Wnt signaling is activated during SA node development, and deletion of β-catenin leads to 
decreased pacemaker cardiomyocyte gene marker expression, such as Isl1, Pitx2, and Tbx3 42. A 
recent study in zebrafish showed that canonical Wnt5b ligands can induce the cardiac pacemaker 
program in Nkx2.5+ cardiomyocyte progenitors, through activation of transcription factors Isl1 
and Tbx18 and silencing of Nkx2.5 43. Wnt signaling also regulates the second heart field (SHF) 
during early development, which broadly is a subset of progenitor cells expressing Isl1 and Nkx2.5. 
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The right ventricular outflow tract (RVOT) and right ventricle (RV) derives from the SHF. 
However, the precise role for Wnt signaling in ventricular maturation is unknown. Additionally, 
our lab has previously shown that ectopic activation of Wnt/β-catenin signaling induces ventricular 
myocytes to become more like conduction system cells as assessed by morphology, gene 
expression, and electrophysiology; Wnt activation downregulates working myocardial genes in the 
ventricles, including Scn5a and Gja1, which encodes for the sodium channel alpha subunit NaV1.5 
and gap junction protein Cx43, respectively 44. Phenotypically, the conduction velocities of Wnt 
gain-of-function (GOF) ventricles are significantly slowed compared to controls, with the RV 
affected more severely. Therefore, there is strong evidence of canonical Wnt signaling regulation 
of cardiac electrophysiology, in both the conduction system and in the ventricles. However, the 
precise mechanisms, whether Wnt signaling directly regulate ion channel or gap junction 
transcription in ventricular cardiomyocytes during development, is unknown. Therefore, I aim to 
address two major questions in the first part of my thesis. First, to determine the transcriptional 
role of canonical Wnt signaling in ventricular maturation. The left and right ventricles develop 
from distinct progenitor populations, namely the first and second heart fields. Canonical Wnt 
signaling promotes the growth and diversification of SHF precursors into right ventricular 
myocardium. Therefore it could be hypothesized that Wnt also contributes to RV maturation 
through chamber-specific transcriptional regulation. The second question is whether canonical 
Wnt signaling directly regulate cardiac electrophysiology genes and if developmental perturbation 
of Wnt results in susceptibility to arrhythmias. Ancillary to the first question, the second question 
asks if the ventricular electrical substrate is affected in a chamber-specific manner, which could 
yield both molecular and functional insight into RV predominant congenital arrhythmias such as 




Understanding arrhythmogenesis and its underlying mechanisms is important for my central 
hypothesis stated above. Cardiac arrhythmias are defined as abnormal rhythms of the heart, and 
can range from benign to life-threatening. Traditionally, arrhythmias have been classified as 
triggered or reentrant45. Triggered arrhythmias manifest from early or delayed 
afterdepolarizations. Early afterdepolarizations (EAD) can occur during action potential 
repolarization, when the cellular ionic conductances and membrane potential becomes suitable for 
depolarization before reaching the resting membrane potential (Figure 1.4.1A). EADs can 
commonly develop when the potassium currents IKr and IKs are reduced, which are observed in 
many cardiac disease conditions46. More specifically, during the plateau phase of the cardiac action 
potential, an EAD can occur if there is a net inward current. This net inward current could be the 
result of reduced repolarizing potassium currents, increase of calcium current, increase in sodium-
calcium exchange current, or increase in late sodium current45.   
 
Figure 1.4.1. Early (EAD) and delayed (DAD) afterdepolarization in cardiac action potentials. A. 
EADs can occur during different phases of repolarization and lead to triggered depolarization. B. 
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DADs are caused by increased intracellular calcium activity and may result in action potential 
depolarization. Figure adapted from Burashnikov and Antzelevitch, 47.  
 
Delayed afterdepolarizations (DAD) can be observed in the setting of increased intracellular 
calcium levels, which manifests in failing hearts48. DADs can be defined as oscillations in the 
membrane potential after repolarization, and are evoked by spontaneous calcium releases from the 
sarcoplasmic reticulum that result in cellular calcium overload49. These membrane potential 
oscillations can increase cellular excitability and cause ectopic depolarizations (Figure 1.4.1B). 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an example of an arrhythmias 
induced by DADs. CPVT has been shown to be caused by mutations to genes encoding for 
calsequestrin and type 2 ryanodine receptor, which lead to calcium leakage from the sarcoplasmic 
reticulum into the cytoplasm50.  
Reentrant arrhythmias are caused by circular electrical activation of myocytes. In normal electrical 
conduction in the heart, the SA nodal activation propagates to the atrial myocardium, converges 
to the AV node, then propagates through the His-Purkinje System to activate the ventricles 
endocardium to epicardium, apex to base. Reentry can occur when the normal conduction pattern 
is disrupted; an activation wavefront fails to propagate normally, and instead propagate 
continuously around a structural or functional obstacle. The wavefront takes a path that leads back 
to the origin, where the tissue has recovered from refractoriness, allow the wavefront to reenter the 
irregular pathway (Figure 1.4.2). Circus reentry can occur when an area of unidirectional block 
exists, and when the length of the reentrant circuit is longer than the wavelength, which is defined 
as the product of the wavefront conduction velocity and the refractory period of the tissue. 
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Therefore, decrease to conduction velocity or increase to action potential duration in the presence 
of unidirectional block can result in reentrant arrhythmias. 
 
Figure 1.4.2. Different models of circular reentry. A. Ring model of reentry. B. Accessory 
pathway reentry from ventricle to atrium in Wolf-Parkinson-White Syndrome. C. Model of reentry 
at a Purkinje-myocardium junction. D. Model of reentry in a linear tissue. Figure adapted from 
Antzelevitch and Burashnikov 45.  
 
Areas of unidirectional block can exist from structural obstacles, such as areas of non-excitable 
tissue like fibrosis, or functional obstacles, such as refractory tissues or dispersion/heterogeneity 
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of repolarization due to intrinsic action potential differences between different myocytes or 
electrical remodeling of a subset of myocytes within the entire heart. Conduction velocity, defined 
as the speed of electrical propagation, is determined mainly by sodium currents, gap junction 
coupling between cells, and cellular capacitance51. Action potential duration and the refractory 
period are determined by potassium, calcium, and sodium currents. While significant amounts of 
research have been done to elucidate the electrophysiologic mechanism of cardiac conduction and 
arrhythmias, the underlying molecular mechanisms, specifically transcriptional and 
posttranslational, are poorly understood. In my thesis, I examine how modulation of the Wnt 
signaling pathway can affect each determinant of conduction velocity, and whether this increases 
the susceptibility of the heart to arrhythmias.  
1.5 Wnt signaling in the adult heart 
Although Wnt signaling is highly active during cardiac development, it is believed to be quiescent 
in the adult heart in normal physiologic conditions. However, in pathologic conditions, many fetal 
genes are reactivated, including Wnt pathway genes52. Many studies have highlighted different 
components of the Wnt pathway that are dysregulated in different injury models, such as Wnt 
ligand and Frizzled receptor genes in myocardial infarction53, Wnt antagonists in hypertrophic 
cardiomyopathy54, GSK-3 in heart failure55, and nuclear β-catenin in myocardial infarction56. Wnt 
signaling in cardiac hypertrophy is well characterized; it has been shown that GSK-3β is a negative 
regulator of hypertrophy and is suppressed via phosphorylation by multiple hypertrophic stimuli 
57. Suppression of GSK-3β leads to β-catenin accumulation and localization to the nucleus. 
Therefore, it is possible that activation of Wnt/β-catenin signaling can result in hypertrophy in the 
adult heart. Despite substantial evidence that Wnt is dysregulated during pathologic remodeling of 
the heart, there are often conflicting results and suggested mechanisms due to the complexity of 
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the pathway. These inconsistencies could also be due to biologic differences in types of 
pathological remodeling, timing of assessment during progression of disease, and different 
methodologies to measure Wnt signaling. Furthermore, although many of the pathologic 
conditions, in which Wnt signaling is perturbed, are strongly associated with conduction 
disturbances and arrhythmias, whether Wnt regulates adult cardiac electrophysiology or 
contributes to arrhythmias in disease directly is unknown. Therefore, in the second part of my 
thesis, I examine the effects of Wnt signaling in regulation of cardiac electrophysiology in the 
adult murine and human heart, and use a novel human organotypic slice culture model to study 
whether inhibition of the GSK-3 pathway, which normally phosphorylates β-catenin, alters adult 
human cardiac electrophysiology in a Wnt/β-catenin dependent manner. 
1.6 The GSK-3 pathway   
Glycogen synthase kinase 3 (GSK-3) is a ubiquitous, constitutively active kinase downstream of 
multiple regulatory pathways. Active GSK-3 generally represses many intracellular processes, and 
is itself inhibited by a variety of cellular stimuli to achieve downstream signaling effects58. GSK-
3 kinases (GSK-3α and GSK-3β) have a substrate-binding domain, which recognizes a 
phosphorylated (primed) residue on the substrate, and a kinase-binding domain, which 
phosphorylates a serine/threonine residue near the primed residue on the substrate. Inhibition of 
GSK-3 leads to escape of β-catenin from phosphorylation among many other GSK-3 substrates, 
and can lead to activation of Wnt/β-catenin signaling. 
In the past 30 years, GSK-3 has emerged as a therapeutic target for neurodegenerative diseases 
and mental disorders, such as Alzheimer’s disease, Rett Syndrome, and bipolar disorder, with 
multiple GSK-3 inhibitors currently in use or in clinical trials59-61. In the heart, GSK-3 has been 
implicated in both congenital and acquired cardiovascular diseases, including cardiomyocyte 
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hypertrophy, diabetic cardiomyopathy, acute cardiac ischemia, and heart failure55, 62-64. Many of 
these conditions show altered GSK-3 activity, in addition to being associated with arrhythmias65-
67. The clinical use of lithium, a classic mood stabilizer and known GSK-3 inhibitor, has been 
reported to cause cardiac conduction abnormalities ranging from benign electrocardiographic 
changes to life-threatening arrhythmias68. Additionally, SB216763 (SB2), a small molecule GSK-
3 inhibitor has been shown to rescue both structural and electrophysiological defects in murine 
and zebrafish models of arrhythmogenic cardiomyopathy65, 69. However, despite growing evidence 
for GSK-3 as a regulator of cardiac electrophysiology, the precise effects and mechanisms remain 
poorly defined. 
One major signaling pathway that is regulated by GSK-3 is the canonical Wnt signaling pathway 
(Figure 1.6.1). In the absence of Wnt ligands, a destruction complex including GSK-3β 
phosphorylates β-catenin, the main transcriptional effector that initiates transcription of Wnt-
responsive genes. Phosphorylation of β-catenin targets it for ubiquitination and degradation, 
resulting in relatively low cytoplasmic levels of β-catenin during homeostasis70. Upon canonical 
Wnt ligand binding to cell surface receptors, parts of the GSK-3β-associated destruction complex 
are recruited to the cell membrane, preventing the destruction complex from phosphorylating β-
catenin. As a result, β-catenin accumulates in the cytoplasm, translocates into the nucleus, and 
activates downstream target genes71. Therefore, pharmacologic inhibition of GSK-3 or disease-
associated decrease of GSK-3 activity can result in activation of Wnt signaling genes. I show that 
both developmental and adult perturbation of β-catenin can affect cardiac electrophysiology and 
increase arrhythmia susceptibility. Specifically, both Scn5a, the gene encoding the major cardiac 
sodium channel subunit NaV1.5, and Gja1, the gene encoding for cardiac gap junction connexin 
43 (Cx43), are transcriptionally regulated by Wnt/β-catenin. β-catenin is also involved in cell-cell 
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adhesion at the adherens junctions, where it binds to N-cadherin72, 73. It has been shown that β-
catenin accumulates at the intercalated discs of hearts with hypertrophic cardiomyopathy, and that 
GSK-3β is simultaneously decreased74-76. Additionally, β-catenin directly associates with Cx43 at 
the intercalated discs77, 78. Therefore, due to its role in regulation of β-catenin, it can be 
hypothesized that decreased GSK-3 activity may regulate Wnt/β-catenin-mediated 
electrophysiological reprogramming. 
 
Figure 1.6.1. The GSK-3 pathway regulates many cellular processes, including the Wnt/β-catenin 







1.7 Objective, results, and significance of thesis 
The overall objective of my thesis work was to determine the role of canonical Wnt signaling in 
the regulation of cardiac electrophysiology. Wnt signaling plays an important role in many 
different stages of cardiac development, including the development of the cardiac conduction 
system. Additionally, mutations to Wnt pathway genes have been linked to congenital arrhythmias, 
and work from our lab has shown that overexpression of β-catenin programs the ventricles to adopt 
more nodal-like electrophysiological properties. Therefore, I hypothesized that the canonical Wnt 
signaling pathway can transcriptionally regulate electrophysiology genes.  
In the first part of my thesis, I focus on elucidating the long-term effects of gain and loss of 
canonical Wnt signaling during cardiac development on subsequent adult electrophysiology by 
modulating the pathway during maturation: after the four chambered heart is formed, but before 
birth. The Wnt pathway involves 19 distinct Wnt ligands 10 Frizzled receptors that signal through 
canonical or non-canonical Wnt signaling20. Therefore, genetic manipulation of canonical Wnt 
signaling is often probed through tissue-specific knockout of the key transcriptional effector β-
catenin. Since β-catenin also plays a key role in cell adhesion, I used an allele of β-catenin that 
abrogates its transcriptional functions but preserves its cell adhesion functions in Wnt loss-of-
function (LOF) studies and an allele of β-catenin that cannot be phosphorylated and targeted for 
degradation in Wnt gain-of-function (GOF) studies, allowing for specificity in probing the 
transcriptional role of Wnt signaling in regulation of cardiac conduction genes in 
cardiomyocytes79, 80. Utilizing both gain and loss-of-function approaches, I show that many genes, 
including those important for conduction, are regulated in a chamber-specific manner. NaV1.5, 
which mediates sodium currents, is down-regulated only in the RV in Wnt GOF mice, while 
connexin 43, a component of gap junctions, is down-regulated in Wnt LOF mice only in the RV. 
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In Wnt LOF mice, many transcripts are exclusively dysregulated in either the RV or LV, and very 
few transcripts are mutually altered in both the RV and LV. Both Wnt gain and loss-of-function 
models reveal dysregulation of Hairy/enhancer-of-split related with YRPW motif protein 2 
(HEY2), a transcriptional repressor known to be regulated by Notch signaling during cardiac 
development81, in the RV only. Genome wide association studies link HEY2 variants with Brugada 
Syndrome, a syndrome of ECG ST elevation associated with right ventricular tachycardia82. Wnt-
mediated regulation of Hey2 is associated with β-catenin binding to nuclear enhancer elements in 
the RV but not LV. Differential β-catenin binding to the Hey2 enhancer in the RV can be seen as 
early as mid-gestation when Hey2 expression is high, and binding in the LV is not observed even 
with increased levels of active β-catenin. Wnt LOF chamber-specific transcriptional effects lead 
to conduction slowing only in the RV, associated with increased susceptibility to ventricular 
tachycardia (VT) with RV stimulation that persists into adulthood and may have implications for 
our understanding of right ventricular-predominant arrhythmias. Overall, I show that embryonic 
perturbation of Wnt signaling in cardiomyocytes lead to right ventricular arrhythmias 
susceptibility in the adult heart through chamber-specific regulation of genes regulating cellular 
electrophysiology. These fundamental insights from signaling pathway to electrical phenotype 
may enable improvements in genetic testing and provide novel avenues for molecular-based 
therapeutics. 
It is traditionally believed that the Wnt pathway is only active during development and becomes 
quiescent in the adult heart. However, in many pathophysiologic conditions, which are commonly 
associated with arrhythmias, it is reactivated and contributes to processes such as hypertrophy. I 
showed in the first part of my thesis that Wnt directly regulates electrophysiology genes during 
development and perturbation of the pathway through β-catenin results in chamber-specific 
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susceptibility to arrhythmias. Therefore, I asked whether Wnt/β-catenin signaling can also regulate 
cardiac electrophysiology in the adult heart, which may yield insight for acquired arrhythmias in 
conditions of Wnt/β-catenin dysregulation. 
In the second part of my thesis, I show that acute pharmacologic GSK-3 inhibition via lithium or 
SB2 reduces conduction velocity (CV) in wild-type mice. Using methodology for culturing human 
left ventricular organotypic slices from non-failing donor hearts, I show that acute treatment with 
SB2 decreases CV after only 3 hours in culture. Reduced CV was associated with decreased 
maximum upstroke velocity (dVm/dtmax) of cardiac action potentials. Simulations conducted in a 
computational model of human myocardium showed that the observed reduction in CV and 
dVm/dtmax can be explained by decreased sodium channel conductance and tissue conductivity. 
Consistent with the modeling results, I found that NaV1.5 protein was decreased in slices treated 
with SB2 at 3 hours. Surprisingly, β-catenin protein levels increased significantly in the chromatin-
bound fraction and not in other subcellular compartments, while transcription of SCN5A, GJA1, 
and other Wnt/β-catenin target genes remained unchanged at this acute time point. My results 
suggest that Wnt-independent pathways, at least in part post-transcriptional processes regulating 
NaV1.5 levels, are involved in acute GSK-3 mediated regulation of electrophysiology.  
Overall, the two major parts of my thesis show that the Wnt pathway regulates cardiac 
electrophysiology both developmentally and in the adult heart, in different manners. While 
developmental perturbation of the canonical Wnt pathway results in differential gene expression 
in the right and left ventricles, this lead to a vulnerable electrical substrate only in the RV of the 
adult heart. These findings not only provide insight into Wnt in cardiac development, but also be 
potentially useful in genetic testing for congenital conduction disorders, developing therapeutic 
targets for right-dominant arrhythmias such as arrhythmogenic cardiomyopathy, and maturation 
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of induced pluripotent stem cell-derived cardiomyocytes, where current protocols sequentially 
inhibit Wnt signaling, resulting in no RV-like cardiomyocytes83. In contrast to the chamber 
specificity observed with developmental activation, adult perturbation of Wnt/β-catenin through 
inducible up-regulation of non-degradable β-catenin resulted in reduced CV within both ventricles 
and susceptibility to arrhythmias. While this chronic elevation of myocardial β-catenin resulted in 
transcriptional repression of Scn5a and slow conduction velocity, acute GSK-3 inhibition in adult 
human hearts also increased nuclear β-catenin and slowed CV, but did not activate Wnt/β-catenin 
target genes, suggesting there is an additional post-transcriptional mechanism. I demonstrate here 
that acute GSK-3 inhibition can alter cardiac conduction resulting in a pro-arrhythmic substrate in 
both mouse and human hearts, and that therapeutic targeting of GSK-3 should consider these 
possible adverse cardiovascular effects.  
 
Many members of my lab have contributed to my thesis work. At the end of each chapter, the 
specific experimental contributions of each lab member is listed. Aditi Khandekar and Kevin Yin 
performed all qPCR experiments. Kevin Yin contributed to Western blot experiments. Stephanie 
Hicks and Kevin Yin contributed to immunofluorescence experiments. Aditi Khandekar and 
Qiusha Guo performed chromatin immunoprecipitation experiments. David Zhang helped in 
optical mapping studies. Patrick Boyle performed computational simulations.   
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Chapter 2: Wnt transcriptionally regulates the heart 
in a chamber-specific manner 
Binding of a Wnt ligand to its cell surface receptor(s) results in inactivation of a destruction 
complex that phosphorylates β-catenin and targets it for degradation84. Inactivation of the 
destruction complex allows intracellular β-catenin to accumulate, eventually resulting in higher 
levels of β-catenin within the nucleus, where it is transcriptionally active. Several Wnt ligands are 
known to be expressed in the developing heart85. To determine the regions within the developing 
heart where canonical Wnt signaling is most active, I assayed for Wnt activity using a transgenic 
mouse with reiterative Tcf/Lef binding sites located upstream of a nuclear-localized GFP 
(TCF/Lef:H2B-GFP 86). Early in development at embryonic day 10.5 (E10.5) and 12.5 (E12.5), 
Wnt activity is highest in the developing right ventricle and atrioventricular regions, eventually 
becoming quiescent in the adult ventricles (Figure 2.1A). At E12.5, Wnt activity is found in a large 
number of myocytes in addition to non-myocytes, with higher density in the trabecular region 
when compared to the compact zone of the RV myocardium, as well as in CMs in the RV outflow 




Figure 2.1. Wnt signaling differentially regulates genes involved in cardiac conduction in 
right and left ventricles. (A) Fluorescent images of TCF/Lef:H2B-GFP transgenic hearts where 
6 Tcf/Lef responsive elements are upstream of an Hsp68 minimal promoter driving GFP. At E10.5 
and E12.5, higher Wnt activity is noted in the primitive right ventricle (RV) and atrioventricular 
region when compared with the left ventricle (LV). Wnt activity is detectable in the right atrium 
but not in the ventricles of a 10-week old adult heart. Scale bar in each image = 500 μm. (B) 
Western blot for total β-catenin in adult control (Ctnnb1flox/+) and littermate Wnt LOF (Mlc2vCre/+; 
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Ctnnb1dm/flox) (n=3 each) demonstrates higher levels of β-catenin protein in the LV at baseline 
when compared with RV. Wnt LOF mice express a truncated β-catenin protein at approximately 
70kDa, in addition to a faint band representing wild type β-catenin at 93kDa, which likely 
represents residual β-catenin within non-myocytes. GAPDH is used for normalization and 
quantification of protein levels is based on wild type β-catenin band density. (C) Venn diagram of 
differentially altered transcripts in adult Wnt LOF (Mlc2vCre/+; Ctnnb1dm/flox) versus littermate 
control (Ctnnb1flox/+) RV and LV (n=3 each genotype). RNA sequencing revealed 690 transcripts 
dysregulated in Wnt LOF RV only, including Gja1 and Hey2, with 715 transcripts dysregulated in 
Wnt LOF LV only, including Scn5a. A small fraction of dysregulated transcripts (83 of 1488, <6%) 
are dysregulated in both ventricles. (D) RT-qPCR in adult Wnt LOF (Mlc2vCre/+; Ctnnb1dm/flox,) 
versus littermate control (Ctnnb1flox/+) mice for selected transcripts (n=5 each genotype). The 
TATA-box binding protein (Tbp, negative control) is unchanged in both ventricles. Hey2 
expression is reduced 4-fold and Gja1 is reduced 3-fold in Wnt LOF RV only, while in contrast, 
Scn5a is upregulated 4-fold in Wnt LOF LV only. (E) Western blot of Nav1.5 (227 kDa) and 
superimposed GAPDH (37 kDa) with quantification based on band density normalized to GAPDH 
shows 60% increase in Nav1.5 in Wnt LOF LV when compared with littermate control LV, with 
no difference in the RV (n=3 each genotype). (F) Western blot of total Cx43 (43 kDa) normalized 
to GAPDH (n=3 each genotype) shows 50% reduction of Cx43 protein levels in Wnt LOF RV 
compared with littermate control RV, while Cx43 protein levels in the LV are unchanged, 
consistent with transcriptional changes seen in (C) and (D). One-way ANOVA and post hoc 
Tukey’s test was performed to determine statistical significance in (B). An equal variance 
Student’s t test was used for all other comparisons. Two-tailed P-values are indicated on the graphs, 




Figure 2.2. Wnt signaling is active in RV and RVOT cardiomyocytes during development. 
(A) Sections from E12.5 TCF/Lef:H2B-GFP reporter mice show Wnt activity, as reported by 
nuclear GFP expression, is highest within the atrioventricular region.  In addition, Wnt signaling 
is found in the right ventricle (RV) and right ventricular outflow tract (RVOT) in myocytes and 
non-myocytes. Immunostaining with α-actinin (red) and DAPI (blue) reveals a high percentage of 
cardiomyocytes have active Wnt signaling at this developmental stage. (B) Higher magnification 
view of the region within the RV from panel A shows higher GFP expression in cardiomyocytes 
of the trabecular region compared with the compact zone of the ventricular myocardium. (C) 
Higher magnification view of the RVOT region from panel A shows Wnt activity is active within 
RVOT cardiomyocytes. Scale bar in each image = 50 μm. RA=right atrium. 
 
Our lab previously reported that developmental Wnt GOF mice have slowed CV predominantly 
affecting the RV44. To further delineate the role of Wnt signaling in regulating cardiac conduction, 
I next assayed the effects in a loss-of-function model. Since β-catenin is integral in transducing the 
Wnt signal into the nucleus but is also important for cell adhesion, I utilize an allele of β-catenin 
that contains a point mutation at the N-terminus and a truncation at the C-terminus rendering it 
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transcriptionally inactive but preserving its role in cell adhesion (Ctnnb1dm 79). When combined 
with a tissue-specific loss of function allele, the only remaining β-catenin expressed within 
ventricular cardiomyocytes is transcriptionally inactive (Wnt LOF, Mlc2vCre/+; Ctnnb1dm/flox). 
Western blots for total β-catenin in wild type animals show higher amounts of β-catenin in the 
adult left ventricle when compared with the right ventricle (Figure 2.1B). As expected, Wnt LOF 
RV and LV reveal a significant decrease in β-catenin levels when compared with littermate 
controls, with a small amount of residual wild type β-catenin at 93 kDa either reflecting expression 
in non-myocytes or incomplete inactivation (Figure 2.1B). Wnt LOF mice also express an 
additional truncated band at 70 kDa from the dm allele (Figure 2.1B). Levels of non-
phosphorylated, active β-catenin also parallel the decrease in total levels, as expected (Figure 2.3).  
 
Figure 2.3. Non-phosphorylated (active) β-catenin levels are higher in control left ventricle 
when compared with right ventricle. Western blot for non-phosphorylated (active) β-catenin in 
adult control (β-catfl/+) and littermate Wnt LOF (Mlc2vCre/+; β-catfl/ DM) mice (n=3 each genotype). 
Wnt LOF mice express a truncated β-catenin protein at approximately 70kDa, in addition to wild 
type β-catenin at 93kDa, as expected from the loss of function model. GAPDH is used for 
normalization, and quantification of protein levels based on band density shows significantly 
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reduced β-catenin in control RV compared to control LV. One-way ANOVA and post-hoc Tukey’s 
test were performed to determine statistical significance. *P<0.05 was considered statistically 
significant. 
 
To determine the global effects of transcriptionally inactive β-catenin within each ventricle, we 
performed RNA sequencing on tissue from adult Wnt LOF and littermate control RV and LV. Of 
the dysregulated transcripts in the RV, 690 of 773 are exclusively changed in the RV, while 715 
of 798 transcripts are exclusively dysregulated in the LV (Figure 2.1C). Only 83 transcripts (<6% 
of the total) are dysregulated in both Wnt LOF RV and LV, and of these 83 transcripts, some 
change in discordant directions (Table 2.1). Notably, RNA-sequencing demonstrates that Hey2 
and Gja1 are down-regulated in the RV, while Scn5a is up-regulated in the LV. Validation via RT-
qPCR demonstrates that Hey2 is downregulated more than 4-fold in the Wnt LOF RV only, while 
its expression in the LV remains unchanged (Figure 2.1D). Scn5a, which encodes the sodium 
channel subunit NaV1.5, is upregulated more than 3-fold in Wnt LOF LV with no change in Wnt 
LOF RV (Figure 2.1D). Gja1, which encodes the predominant ventricular gap junction isoform 
connexin43 (Cx43), is reduced 4-fold within the RV while its expression is unchanged in the LV 
(Figure 2.1D). Consistent with the differential effect on transcript levels, Western blots show 60% 
increase in NaV1.5 protein in Wnt LOF LV compared with littermate controls and no change in 
the RV (Figure 2.1E). Similarly, there is a 50% reduction of total Cx43 in Wnt LOF RV compared 
with littermate controls, with no change in the LV (Figure 2.1F).  
Given that we previously showed conduction slowing in Wnt GOF mice primarily affecting the 
RV 44, I asked whether these molecular determinants of conduction are similarly dysregulated with 
Wnt activation. Surprisingly, we found that NaV1.5 is reduced to 48% of littermate control levels 
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in the Wnt GOF RV (Mlc2vCre; Ctnnb1flox(ex3)/+), while levels are unchanged in Wnt GOF LV 
(Figure 2.4A). Connexin43 levels are unchanged in Wnt GOF mice in both the RV and LV (Figure 
2.4B). This data reveals that the molecular determinants of cardiac conduction are dysregulated by 
Wnt signaling during development primarily within the RV, though gain and loss of function 
regulates distinct channels.  
 
Figure 2.4. NaV1.5 protein levels are decreased in Wnt gain-of-function mice only in the right 
ventricle, while Cx43 protein levels are unchanged. (A) Western blot for NaV1.5 and GAPDH 
with quantification based on band density normalized to GAPDH shows a 48% decrease of NaV1.5 
in Wnt GOF RV when compared with littermate control RV, with no differences in the LV (n=3 
each genotype). (B) Western blot of Cx43 normalized to GAPDH (n=3 each genotype) shows no 
difference in Wnt GOF Cx43 protein levels compared to controls. An equal variance Student’s t 




Figure Contributions: Rich Gang Li (RGL) performed all Western blots and made all the figures. 
Kevin Tiankai Yin (KTY), RGL, and Stephanie Hicks (SH) performed immunofluorescence. Aditi 
Khandekar (AK) performed all qPCRs and processed samples for RNAseq. RGL and AK analyzed 


























Table 2.1. List of transcripts changed in both Wnt LOF RV and LV  






1110008P14Rik  1.22 0.0378 -1.35 0.006 
A930005H10Rik -1.54 0.0201 -1.81 0.0057 
Abra -1.30 0.0374 -1.52 0.0033 
Actc1 1.17 0.0352 -1.23 0.0087 
Adcy4 -1.25 0.0391 -1.31 0.0171 
Adhfe1 -1.32 0.0063 -1.25 0.0248 
Alas2 -1.22 0.0394 1.24 0.0397 
Amz1 -1.50 0.0189 2.09 0.0008 
Ano4 1.43 0.0010 1.38 0.0029 
Aqp1 -1.41 0.0008 -1.22 0.0266 
Auts2 1.19 0.0318 1.26 0.0067 
B330016D10Rik 1.31 0.0226 1.29 0.035 
Bcl11b 1.54 0.0037 1.41 0.0239 
Bicd1 1.25 0.0107 1.18 0.0461 
Brca2 1.23 0.0482 1.28 0.0231 
C920006O11Rik 2.79 0.0018 2.07 0.0137 
Cnih4 1.38 0.0066 1.26 0.0399 
csf1 1.37 0.0010 1.26 0.01 
Decr2 -1.18 0.0148 -1.14 0.0422 
Dixdc1 1.32 0.0214 1.29 0.0391 
Dnajc5 1.51 0.0250 1.44 0.0452 
Dnm3os 1.26 0.0319 1.25 0.0392 
Dysf 1.12 0.0319 1.17 0.0072 
Ednrb -1.29 0.0283 -1.59 0.0007 
Fabp5 -1.57 0.0025 -1.54 0.0039 
Fam220a -1.13 0.0454 -1.17 0.0147 
Fasn 1.15 0.0290 1.16 0.0232 
G0s2 -1.31 0.0371 -1.35 0.0302 
Gm15334 1.30 0.0347 1.37 0.0123 
Gm15446 2.17 0.0018 1.56 0.0361 
Gm17203 1.41 0.0480 1.69 0.0061 
Gm24041 -1.47 0.0219 1.50 0.0211 
Gm28979 1.40 0.0190 1.34 0.0438 
Gm6612 -5.38 0.0218 -4.50 0.0414 
Heatr5b -1.31 0.0028 -1.18 0.05 
Hsd17b7 6.76 0.0015 4.91 0.0059 
Hsp90aa1 -1.30 0.0250 -1.35 0.0101 
Hspa12a 1.36 0.0021 1.34 0.0029 
Ky 1.26 0.0086 1.18 0.045 
Lgi2 2.55 0.0022 3.03 0.0008 
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Lgr6 1.48 0.0147 1.38 0.0379 
Lrif1 1.16 0.0298 -1.14 0.0477 
Ly6e 1.24 0.0097 -1.24 0.0109 
Ly75 1.32 0.0439 1.44 0.0153 
Maf -1.22 0.0163 1.28 0.0135 
Mical2 -1.18 0.0334 -1.20 0.024 
Muc5b -1.59 0.0472 2.28 0.0032 
Mylk4 1.22 0.0356 1.23 0.0279 
Mzt1 1.20 0.0432 1.24 0.0232 
Nfia 1.22 0.0120 1.22 0.0132 
Nxpe4 17.36 0.0152 5.13 0.0429 
Olfml2b -1.40 0.0014 -1.40 0.0018 
P4ha1 -1.25 0.0412 -1.30 0.0209 
Pcp4l1 1.31 0.0079 1.33 0.0072 
Pdgfc 2.09 0.0017 1.46 0.0484 
Plb1 1.49 0.0314 1.50 0.0378 
Plin2 -1.33 0.0008 -1.23 0.0083 
Plscr2 1.14 0.0485 1.15 0.0356 
Ppil1 -1.48 0.0208 -1.61 0.0098 
Ppp1r16b -1.18 0.0295 -1.29 0.0021 
Prox1 1.21 0.0140 1.20 0.0218 
Rab37 2.06 0.0149 1.81 0.0266 
Rab6b 6.19 0.0035 3.39 0.0297 
Reps2 1.25 0.0471 1.35 0.0118 
Rgs4 -1.34 0.0444 -1.37 0.0334 
Ripor2 1.34 0.0198 1.49 0.0036 
Rnf150 1.16 0.0192 1.15 0.0241 
Rpl26 2.20 0.0304 3.07 0.0061 
Rps2-ps13 12.79 0.0158 15.61 0.0277 
Rtca -1.25 0.0378 -1.28 0.0295 
Rybp 1.32 0.0372 -1.35 0.0268 
Serpine1 -1.41 0.0016 -1.39 0.0024 
Setbp1 1.24 0.0500 1.26 0.0397 
Slc12a9 1.38 0.0170 1.41 0.0097 
Slc38a1 1.56 0.0176 1.45 0.0371 
Smoc2 -1.18 0.0242 -1.16 0.0459 
Sqstm1 -1.17 0.0307 -1.21 0.0139 
Tjap1 -1.19 0.0412 -1.22 0.0236 
Tuba1a -1.31 0.0447 -1.32 0.0421 
Tubb2b -2.00 0.0146 -1.84 0.0276 
Uba52 -1.29 0.0266 -1.33 0.0248 




Chapter 3: Hey2 is a direct target of Wnt only in the 
right ventricle 
To preferentially identify upstream Wnt targets which may exert an effect during development, we 
performed RNA sequencing comparing global gene expression in developmental Wnt GOF 
(αMHC-Cre; Ctnnb1flox(ex3)/+) with littermate control E12.5 embryonic ventricles. Differential 
expression analysis reveals 36 differentially regulated genes (Figure 3.1A, Table 3.1). Interestingly, 
Hey2 is up-regulated in Wnt GOF embryonic ventricles, and was also down-regulated in Wnt LOF 
RV (Figure 2.1C, D). Hey2 is a transcriptional repressor highly expressed in both ventricles during 
embryogenesis, with relatively lower expression in postnatal hearts 87. Hey2 has been associated 
with Brugada Syndrome and ventricular transmural regulation of ionic currents 88. Additionally, 
Hey2 is a known direct Notch target, but it has long been postulated that regulation of Hey2 
expression in the ventricles may not simply reflect a role of Notch signaling, and that Notch-




Figure 3.1. Hey2 is a direct target of Wnt signaling in the right ventricle with differential 
enhancer binding of β-catenin. (A) Heat map representation of RNA sequencing of Wnt GOF 
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(αMHC-Cre; Ctnnb1fl(ex3)/+) versus littermate control (Ctnnb1fl(ex3)/+) embryonic ventricles (n=6 
each) reveals 36 differentially-regulated transcripts including Hey2. (B) Genomic regions of 
murine Hey2 delineating known upstream cardiac enhancers with location relative to the 
transcription start site, and putative Notch and Wnt transcriptional effector binding sites. (C) ChIP 
for β-catenin in embryonic day 12.5 (E12.5) Wnt GOF (αMHC-Cre; Ctnnb1fl(ex3)/+) and littermate 
control (Ctnnb1fl(ex3)/+) ventricles (RV and LV combined, n=3 each) shows basal binding to the 
positive control bhlh2D locus, without binding at the negative control Scn10a locus, Hey2 
Enhancer (Enh) 1, nor Enh 2. 7-fold enrichment of β–catenin was detected in controls at the 
consensus Wnt-responsive element within Hey2 Enh 3, with further 19-fold enrichment in Wnt 
GOF ventricles (a threshold of 4-fold enrichment over IgG was considered binding). (D) ChIP for 
β-catenin in wild type (WT) E12.5 RV versus LV reveals 4-fold enrichment of β-catenin binding 
at Hey2 Enh3 in RV, without enrichment in the LV, at this early developmental stage (n=4). (E) 
ChIP for H3K27ac in WT E12.5 RV versus LV shows enrichment at the positive control Gata4 
locus, but not at the negative control gene desert (neg) in both RV and LV. There is more than 12-
fold enrichment of H3K27ac in the RV at Hey2 Enh3, however, in contrast there is less than 4-
fold enrichment in the LV (n=4). (F) ChIP in adult RV shows β-catenin binding at the positive 
control bhlh2D locus, as well as Hey2 Enh3 in controls (Mlc2vCre/+), without further enrichment 
in littermate Wnt GOF mice (Mlc2vCre/+; Ctnnb1fl(ex3)/+). Binding is not detected at the negative 
control Scn10a promoter, nor at Hey2 Enh1,2 (n=4 each). In adult control and Wnt GOF LV, β-
catenin binds at the positive control bhlh2D locus, without enrichment at the negative control 
Scn10a promoter, nor Hey2 Enh1-3. β-catenin binding at Hey2 Enh3 is not detected in Wnt GOF 
LV despite increased β-catenin levels, suggesting that levels alone may not account for the lack of 
Enh3 binding in the LV (n= 4 each). (G) qRT-PCR from inducible Wnt GOF mice (iWnt, 
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αMHCrtTA; TetO-Cre; Ctnnb1fl(ex3)/+), where Wnt signaling was induced in adulthood, versus 
control (TetO-Cre; Ctnnb1fl(ex3)/+) mice, shows increased expression of the direct Wnt target Axin2 
in both ventricles, no change in expression of Tbp (negative control), while Hey2 expression 
increases in the RV only (n=4 each). An equal variance Student's t-test was used for comparisons, 
with all two-tailed P-values indicated. *P<0.05 considered statistically significant. 
 
To determine whether Hey2 may be a direct Wnt target, we performed a bioinformatics analysis 
on Hey2 regulatory regions. Three Gata-responsive cardiac enhancers have previously been 
identified upstream of Hey2 with differential expression patterns in the embryonic heart (Figure 
3.2) 89. All three enhancers (Enh1-3) contain Gata4 binding sites, and we identified consensus 
RBP-J binding motifs within enhancer 1 (Enh1) and near the TSS, consistent with Hey2 as a known 
direct Notch target (Figure 3.1B). Members of the Tcf/Lef transcription factor family associate 
with DNA targets in repressive complexes in the absence of Wnt signaling. When canonical Wnt 
signaling is active, β-catenin complexes with Tcf/Lef to displace the repressive complex and 
activate transcription 84. We identified a putative Tcf/Lef Wnt response element90 within Hey2 
enhancer 3 (Enh3) (Figure 3.1B), a 1343 base pair enhancer 82% conserved between mice and 
humans, with conserved Tcf/Lef and GATA binding sites. To determine whether Enh3 may confer 
Wnt-responsiveness, we first determined whether β-catenin is associated with this region in 
embryonic ventricles by performing chromatin immunoprecipitation (ChIP) followed by qPCR. In 
control ventricles, we detected more than 20-fold enrichment of β-catenin at the positive control 
Bhlh2 locus relative to IgG, while we did not detect β-catenin binding to a negative control region 
within the Scn10a gene that functions as a Scn5a enhancer (Figure 3.1C) 91. Similarly, β-catenin 
does not bind to Enh1 nor Enh2, while there is 7-fold enrichment at Hey2 Enh3 (Figure 3.1C). We 
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next asked whether Hey2 up-regulation (Figure 3.1A) correlates with increased β-catenin binding 
to the Hey2 enhancer in developmental Wnt GOF (αMHC-Cre; Ctnnb1flox(ex3)/+) embryonic 
ventricles when compared with littermate controls. While no further enrichment of basal β-catenin 
binding was seen in E12.5 Wnt GOF embryos at the Bhlh2D locus, 19-fold enrichment was 
observed at Hey2 Enh3, demonstrating dynamic binding (Figure 3.1C). 
 
Figure 3.2. ENCODE data of mouse heart H3K4me1 and H3K27ac sequencing shows peaks 
near Hey2 enhancers. Mouse heart ChIP-seq for H3K4me1 and H3K27ac from ENCODE in 
embryonic day 10.5 and 12.5 (E10.5, E12.5), postnatal day 0 (P0), and adult (8 Weeks) show 
enrichment peaks at all three Hey2 enhancer sequences at E10.5, E12.5 and PO compared to 
control, with decreased amplitude of the peaks in adult hearts.  This is consistent with the known 




Given that Wnt LOF resulted in decreased Hey2 expression only in the RV (Figure 2.1C, D), we 
wondered whether chamber-specific patterns of Hey2 expression are present during embryonic 
stages. To address this, we dissected wild type E12.5 embryos and pooled 4 primitive RV (bulbus 
cordis region without the outflow tract region) and LV for gene expression studies, and 12 RV and 
LV for each ChIP technical replicate. We found approximately 1.8-fold higher Hey2 expression in 
the RV compared to the LV at E12.5 (p=0.034, Figure 3.3A). ChIP for β-catenin shows binding at 
Hey2 Enh3 in the primitive RV but not in the LV (Figure 3.1D). We then performed ChIP for 
H3K27ac, a modification to Histone H3 that correlates with active enhancers, on wild type E12.5 
RV and LV.  We found over 12-fold enrichment in the RV at Hey2 Enh3, without significant fold 
enrichment in the LV, suggesting that even at this stage there is differential chromatin 
configuration in the RV and LV (Figure 3.1E). 
 
Figure 3.3. Hey2 (Hrt2) expression in embryonic wild type and in adult Wnt gain-of-function 
ventricles. (A) qRT-PCR of WT E12.5 primitive right and left ventricles (n= 4 each) shows 1.8-
fold higher Hey2 expression in embryonic RV compared to LV. (B) Comparison of RV and LV of 
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control (Mlc2vCre/+) versus Wnt GOF (Mlc2vCre/+; Ctnnb1fl(ex3)/+) shows increased Hey2 expression 
in RV only (n=4 each group). An equal variance Student’s t test was used for comparisons. 
*P<0.05 was considered statistically significant. 
 
Since Wnt activity is higher in early embryonic RV versus LV, we asked whether levels of active 
β-catenin can account for differential enhancer binding between ventricles. If levels alone are 
sufficient to dictate differential binding, we might expect to find enhanced β-catenin binding to 
the LV Hey2 Enh3 under conditions where active β-catenin levels are higher in the LV. In wild 
type adult mice, Western blots of total and non-phosphorylated (active) β-catenin demonstrate 
more than 1.5-fold higher levels of total β-catenin (Figure 2.1B) and active β-catenin (Figure 2.3) 
in the adult LV compared with RV. Despite higher levels of active β-catenin in the adult LV, we 
observe over 5-fold β-catenin enrichment at the Hey2 Enh3 locus only in the RV, while binding to 
the LV enhancer is not observed (Figure 3.1F). To further test whether active β-catenin levels 
alone can overcome binding to Enh3 in the LV, we assayed for β-catenin binding in developmental 
Wnt GOF mice. While in the Wnt GOF RV we observe over 5-fold β-catenin enrichment at the 
Hey2 Enh3 locus (Figure 3.1F), despite increased levels of active β-catenin binding was not 
detected at Hey2 Enh3 in the LV (Figure 3.1F). Consistent with these findings, Hey2 gene 
expression is up-regulated in the RV only (Figure 3.3B). Furthermore, in an adult “tet-on” 
inducible Wnt GOF model (iWnt, αMHCrtTA; TetO-Cre; Ctnnb1fl(ex3)/+), Hey2 gene expression is 
increased by 6-fold compared to control (TetO-Cre; Ctnnb1fl(ex3)/+) in the adult RV only, while the 
Wnt target Axin2 is up-regulated to a similar extent in both RV and LV (Figure 3.1G). Taken 
together, these results suggest that differential regulation of Hey2 by Wnt persists into adulthood 
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and is not due to exclusion of active β-catenin from left ventricular nuclei, and is likely due to 
differential chromatin structure existing from early developmental stages. 
 
Figure Contributions: AK and Qiusha Guo (QG) performed all ChIP experiments and qPCRs. 
























1700080G11Rik 5.95 0.0422 
Adamts3 -1.54 0.0494 
Angpt1 1.56 0.0343 
Aplp2 1.64 0.0378 
Bco2 7.89 0.0289 
Ccnd2 1.42 0.0378 
Cdh6 2.38 0.0286 
Col23a1 1.47 0.0378 
Creg2 5.76 0.0378 
Cyp26b1 5.97 0.0378 
Dkk4 10.94 0.0098 
Eln -3.67 0.0378 
Fam213b -1.51 0.0472 
Fibcd1 17.19 0.0343 
Gm26984 5.65 0.0422 
Gm29521 11.06 0.0104 
Gnb1 -1.51 0.0343 
Hey2 1.34 0.0343 
Hsbp1l1 2.18 0.0378 
Hspa2 2.07 0.0098 
Jakmip3 6.93 0.0378 
Lgi1 5.89 0.0378 
Limch1 1.33 0.0472 
Notumos 6.36 0.0343 
Nupr1 -2.98 0.0022 
Rab33a 2.87 0.0343 
Rgs5 -6.37 0.0209 
Rnf43 3.96 0.0453 
Rxfp1 5.07 0.0378 
Scn4b 5.48 0.0422 
Skap1 5.49 0.0343 
Slc13a4 3.48 0.0422 
Smoc2 -2.01 0.0286 
Sp5 16.74 0.0286 
Tenm2 1.84 0.0289 




Chapter 4: Wnt loss-of-function results in differential 
electrophysiologic effects in right versus left ventricle 
Given the observed differential expression of molecular determinants of conduction in Wnt LOF 
RV versus LV, I asked whether there may be chamber-specific electrophysiologic effects. Using 
optical mapping techniques together with programmed electrical stimulation, I measured the 
conduction velocity (CV) of Wnt LOF and littermate control mice (Figure 4.1A,B, n=7 each group). 
When stimulated within the physiological range (8 Hz Figure 4.1, 10 and 12 Hz Figure 4.2), 
longitudinal CV in the RV is significantly slower in Wnt LOF mutants when compared with 
littermate controls (52.7±2.0 versus 68.2±0.9 cm/s, 8 Hz), while transverse CV is unchanged. In 




Figure 4.1. Conduction velocity is slower in Wnt loss-of-function right but not left ventricles. 
(A) Representative reconstructed electrical activation maps from the RV (top) and LV (bottom) 
obtained during an optical mapping experiment with epicardial stimulation in Wnt LOF 
(Mlc2vCre/+; Ctnnb1dm/flox, right panel) and littermate control (Ctnnb1flox/+, left panel) hearts. Data 
were recorded during stimulation at 8Hz. More isochrones are visible on the Wnt LOF RV 
epicardial surface indicating slower conduction velocity (CV). Scale bars = 1 mm. (B) Calculated 
longitudinal and transverse CVs from control and Wnt LOF hearts (n=7 each genotype) show RV 
longitudinal CV is decreased by 23% in Wnt LOF RV compared with control (52.7 cm/s versus 
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68.2 cm/s) with decreased anisotropy (1.32 versus 1.66). In contrast, there is no difference in CV 
between Wnt LOF and control in the LV. An equal variance Student’s t test was used for 
comparisons, *P<0.05 were considered statistically significant. (C) Immunostaining of total Cx43 
(red) and N-Cadherin (green) in control and littermate Wnt LOF shows co-localization without 
evidence of Cx43 lateralization in both RV and LV. Long = longitudinal, Trans = transverse, Scale 
bars = 20 µm. 
 
 
Figure 4.2. Conduction velocity is slower in Wnt loss-of-function right ventricles when paced 
at physiologic rates. Longitudinal and transverse conduction velocities from control and Wnt LOF 
hearts (n=7 each genotype) show significantly reduced RV longitudinal CV compared with control 
RV (A) at 10Hz and 12Hz stimulation, while both longitudinal and transverse CV is unchanged in 
the LV (B). An equal variance Student’s t test was used for comparisons, *P<0.05 were considered 
statistically significant. Long = longitudinal, Trans = transverse. 
 
Large changes in a single conduction parameter or modest changes in a combination of parameters 
are needed to exceed the limits of conduction reserve and impair conduction. To delineate whether 
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factors in addition to reduced Cx43 levels may contribute to conduction slowing in Wnt LOF mice, 
we assessed cardiac morphology, fibrosis, and CM cell size (Figure 4.3). While mice carrying the 
global Ctnnb1dm allele are uniformly smaller in size when compared with wild type littermates 
likely due to non-cardiac effects of this allele, the heart weight to tibia length ratio and CM cell 
size is unchanged in Wnt LOF mice (Figure 4.3). In addition, no structural heart defects or 
increased fibrosis were observed in Mlc2vCre/+; Ctnnb1dm/flox Wnt LOF mice. Immunostaining 
shows normal localization of Cx43 at the intercalated disc, with strong co-localization together 
with N-Cadherin (Figure 4.1C). Previous studies have shown that phosphorylation of Cx43 at 
Serine 368 can lead to altered conductance and internalization of gap junctions 92, 93. Using an 
antibody specific for this phosphorylated Cx43 isoform, immunostaining demonstrates no 
significant change in Cx43 localization, while quantification by Western blot shows a similar level 
of protein reduction to that observed with total Cx43 in the RV (Figure 4.4). Taken together, the 
absence of additional changes suggests that transcriptional down-regulation leading to reduced 




Figure 4.3. Structural determinants of conduction velocity are not changed in Wnt loss-of-
function hearts. Representative images of Masson’s Trichrome stain of control (A) and littermate 
Wnt LOF (B) heart shows no gross structural heart defects (n=3 each genotype). Scale = 1000 μm. 
Wheat germ agglutinin staining of cell membranes shows no gross difference in transverse 
myocyte cross-sectional area between control (C) and littermate Wnt LOF (D) RV 
cardiomyocytes. Representative cells used for quantification are outlined in white. Only 
ventricular myocytes sectioned perpendicularly, as evidence by circular morphology, were 
included in the analysis. Scale = 25 μm. (E) Quantification of RV and LV myocyte cross-sectional 
area shows no significant differences between control and Wnt LOF hearts (n=3 each genotype). 
Each data point represents the average area of more than 100 cells from the same heart. (F) Wnt 
LOF mice are smaller when compared with littermate control mice of the same age, however, the 
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heart weight to tibia length ratio is not significantly different (n=6 each genotype). An equal 




Figure 4.4. Levels and localization of phospho-Connexin 43 (pCx43) are unchanged in Wnt 
loss-of-function RV. (A) Representative image of immunostaining of pCx43 (red) and N-
Cadherin (green) shows strong co-localization at the intercalated disc in both control (Ctnnb1flox/+) 
and littermate Wnt LOF (Mlc2vCre/+; Ctnnb1dm/flox) RV without evidence of lateralization (n=3 
each genotype). Scale = 20 μm. (B) Western blot comparing levels of pCx43 (~42 kDa) in control 
RV and littermate Wnt LOF RV (n= 3 each genotype). GAPDH is used for normalization, and 
quantification of protein levels based on band density shows a 50% reduction of pCx43 in Wnt 
LOF RV, similar to the reduction of total Cx43 levels. An equal variance Student’s t test was used 




Conduction velocity is directly related to CM cell coupling through gap junctions and membrane 
sodium current. To gain further insight into the molecular basis for CV slowing, I performed 
intracellular sharp microelectrode recordings on Langendorff-perfused hearts (Figure 4.5A-G). 
Interestingly, in control hearts the maximum upstroke velocity (dVm/dtmax) is higher in RV 
subepicardial cells when compared with LV subepicardial cells (Figure 4.5D, Table 4.1). Previous 
reports in dispersed cells have not reported this right versus left difference 94. I did not observe 
differences in the resting membrane potential (RMP) or action potential amplitude (APA) between 
control RV and LV (Figure 4.5F,G), while the action potential duration at 90% repolarization 
(APD90) is significantly longer in LV myocytes (Figure 4.5E), consistent with previous reports 95. 
 
Figure 4.5. Increased excitability in Wnt loss-of-function right ventricular cardiomyocytes. 
Averaged action potential from control (blue) and Wnt LOF (red) RV (A) and LV (B) myocytes 
recorded with sharp microelectrodes reflecting a composite of all cells recorded. (C) Zoom of a 
portion of the action potential from (A) including Phase 0 with tangent lines drawn through the 
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point of maximum upstroke velocity (dVm/dtmax) demonstrates a greater dVm/dtmax in Wnt LOF RV 
cells when compared with littermate controls (251 mV/ms vs. 229 mV/ms, p=0.005). (D-G) 
Graphical representation of RV and LV action potential parameters from control and littermate 
Wnt LOF hearts. dVm/dtmax and APD90 values differ between control RV and LV at baseline, 
consistent with previous reports. The dVm/dtmax is significantly higher in Wnt LOF RV compared 
to control RV cells, while maximal APA, RMP, and APD90 are unchanged in Wnt LOF RV cells. 
In contrast, no action potential parameters are different between control and Wnt LOF LV cells. 
At least ten cells per condition reflecting 20 to 100 APs per cell were averaged to yield one value 
per mouse. The average of n=5 mice per genotype is represented with mean±SEM. Control mice 
are Ctnnb1flox/+ and Wnt LOF are Mlc2vCre/+; Ctnnb1dm/flox. Statistics were performed using a two-
way ANOVA followed by a post-hoc Tukey’s multiple comparisons test. RMP = resting 
membrane potential; APA = action potential amplitude; dVm/dtmax = maximal upstroke velocity; 
APD90 = duration of the action potential at 90% repolarization. *P<0.05 considered statistically 
significant, ns = not significant. 
 
When compared with littermate controls, Wnt LOF RV CMs exhibit increased maximum upstroke 
velocity (dVm/dtmax 229±6.4 versus 251±4.3 V/sec, p=0.005, Figure 4.5A,C,D, Table 4.1), while 
the LV maximum upstroke velocity remains unchanged (dVm/dtmax 180.6±9.2 versus 173.7±7.5 
V/sec, Figure 4.5B,D). The APA, RMP, and APD90 are similar between control and Wnt LOF in 
both RV and LV (Figure 4.5E-G). In whole organ physiology, increased maximum upstroke 
velocity can be due to either enhanced phase 0 depolarization of the fast sodium current (which 
would result in increased conduction velocity), or from reduced intercellular gap junction coupling 
(which would result in decreased conduction velocity). While in an isolated cell INa,max is the sole 
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determinant of dVm/dtmax, reduced coupling in tissue changes the source-sink relationship. 
Increased upstroke velocity in the setting of reduced coupling results from greater confinement of 
depolarizing charge to individual cells (decreased electrical load), thereby increasing the available 
charge for local depolarization and accelerating the rate of depolarization to cause a steeper AP 
upstroke. Therefore, taken together, increased maximum upstroke velocity in the absence of 
structural changes in Wnt LOF RV is consistent with decreased gap junction coupling as the 
leading contributor to conduction slowing.  
Table 4.1. Microelectrode Recordings 
 Control RV 
n=5 




Wnt LOF LV 
n=5 
RMP, mV -79.6± 0.5 -78.7 ± 0.6 -79.0 ± 0.4 -78.6 ± 0.6 
APA, mV 87.6 ± 0.9 90.1 ± 1.0  81.2 ± 1.4 83.7 ± 1.5 
dVm/dtmax, V/sec 230.0 ± 6.4  250.5 ± 4.3* 180.6 ± 9.2^ 173.8 ± 7.5 
APD90, msec 48.9 ± 5.1  43.7 ± 2.7 65.2 ± 5.2^ 57.3 ± 2.6 
Action potential parameters from 8-10 cells are averaged to yield a value per mouse. The average 
result from n=5 mice per genotype are expressed as mean ± SEM. Control indicates Ctnnb1flox/+ 
and Wnt LOF indicates Mlc2vCre/+; Ctnnb1dm/flox experimental groups. Statistics were performed 
using a one-way ANOVA followed by a Tukey’s multiple comparisons test. Values of P<0.05 
were considered statistically significant in comparison between control RV versus control LV 
(^P<0.05), as well as Wnt LOF vs. control mice (*P<0.05). RMP = resting membrane potential; 
APA = action potential amplitude; dVm/dtmax = maximal upstroke velocity; APD90 = duration of 




Figure Contributions: RGL performed all optical mapping, microelectrode, and Western blot 









Chapter 5: Wnt loss-of-function hearts are 
predisposed to ventricular tachycardia originating 
from the right ventricle 
To determine whether Wnt LOF mice have perturbation of baseline conduction intervals, EKGs 
were performed in mice while conscious or under light isoflurane sedation. Consistent with our 
previous report demonstrating that Wnt signaling programs the electrical phenotype of the 
atrioventricular junction 44, the PR interval is shorter in Wnt LOF mice when compared with 
littermate control (34.5±0.7 versus 37.7±0.8 ms) while the heart rate, P wave duration, QRS and 
QT intervals are unchanged (Table 5.1). It is often difficult to induce and sustain VT in mice in 
part due to the small ventricular surface area. To determine whether Wnt LOF mice exhibit 
spontaneous ventricular arrhythmias, I performed conscious telemetric monitoring on caged, 
moving mice. I did not detect spontaneous arrhythmias during one week of continuous telemetric 
monitoring. Given that increased sympathetic tone can often trigger arrhythmias in inherited and 
acquired cardiac disease, I injected Wnt LOF mice daily with isoproterenol. Though isoproterenol 




Table 5.1. EKG intervals, Ex Vivo and In Vivo Programmed Electrical Stimulation 
EKG Intervals 
 Control Wnt LOF 
Conscious HR (bpm) 692 ± 16 718 ± 12 
Isoflurane HR (bpm) 488 ± 15 497 ± 23 
P wave duration (msec) 12.5 ± 1.3 10.5 ± 0.7 
PR (msec) 37.7 ± 0.8 34.5 ± 0.7* 
QRS (msec) 10.3 ± 0.7 10.1 ± 0.4 




Ex Vivo Programmed Electrical Stimulation 
 Control Wnt LOF 
Mice with VT following RV stim  0/7 5/7* 
Mice with VT following LV stim 0/7 0/7 
Duration VT (s) N/A 94 ± 50 
VT cycle length (msec) N/A 48 ± 3 
Mice with spontaneous NSVT/VT 0/7 2/7 
Total episodes spontaneous NSVT/VT 0 734 
 
In Vivo Programmed Electrical Stimulation 
 Control Wnt LOF 
Heart Rate (bpm) 521 ± 21 572 ± 45 
V to A 1:1 (msec) 90 ± 6  96 ± 6  
V to A Wenckebach (msec) 83 ± 5 88 ± 5 
RVERP120 (msec) 38 ± 3 28 ± 3* 
Episodes NSVT/VT (S1S2) 0 10* 
Total episodes NSVT/VT 0 31* 
 
EKG Intervals. EKGs were performed on conscious Wnt LOF (Mlc2vCre/+; Ctnnb1dm/flox, n=6) 
and littermate control (Ctnnb1flox/+, n=6) mice to determine HR, as well as during isoflurane 
sedation to determine HR and additional conduction parameters. Statistics were performed using 
unpaired t tests with Welch’s correction. *P<0.05, data are expressed as mean ± SEM. 
 
Ex Vivo Programmed Electrical Stimulation. Langendorff-perfused hearts from Wnt LOF 
(Mlc2vCre/+; Ctnnb1dm/flox, n=7) and littermate control (Ctnnb1flox/+, n=7) mice were stimulated with 
40 beats of an S1 drive train at 8 Hz, 50 beats at 10 Hz and 60 beats at 12 Hz first on the RV 
followed by the LV. Episodes of VT were defined as ventricular activation faster than atrial 
activation with AV dissociation persisting longer than 2 s. Episodes of both monomorphic VT and 
polymorphic VT were observed, and representative activation maps and movies from the same 
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hearts during sinus rhythm and ventricular tachycardia are shown in Figure 6 and Supplemental 
Videos 1 and 2. The average VT cycle length is shown for monomorphic VT episodes. 2 of 7 mice 
also developed frequent episodes of spontaneous NSVT/VT during the protocol. A Fisher’s exact 
test was used to determine significance between number of mice with and without VT. *P<0.05, 
data are expressed as mean ± SEM. 
In Vivo Programmed Electrical Stimulation. Isoflurane-sedated mice (same cohort used for 
EKGs, n=6 mice) were subjected to an invasive EP study via cannulation of the right internal 
jugular vein. The same stimulation protocol was performed on each mouse. The His electrogram 
was not visualized in the majority of mice, therefore AH and HV intervals are not shown. NSVT 
is defined as between 3 beats to 2 seconds of VT, while episodes of VT are defined as those lasting 
longer than 2 sec. Episodes of NSVT/VT elicited from 1 extrastimulus (S1S2) are delineated from 
total number of episodes, which includes those elicited from 2 or 3 extrastimuli and burst pacing. 
Statistics on heart rate, V to A conduction, and RVERP were performed using unpaired t tests with 
Welch’s correction. A Fisher’s exact test was used to determine significance between number of 






Figure 5.1. Heart rate as measured by telemetry is increased following isoproterenol 
injection. Heart rate recorded via telemetry in control (Ctnnb1flox/+, n= 1, red) and Wnt LOF 
(Mlc2vCre/+; Ctnnb1dm/flox, n= 3, black) mice shows increased HR following intraperitoneal 
isoproterenol injection. However, no spontaneous arrhythmias were observed in either condition. 
A paired t test was used to determine significance between baseline and isoproterenol HR. *P<0.05 
was considered statistically significant. 
 
It has previously been shown that intrinsic asymmetry in electric properties of tissue, for example 
excitability, refractory periods, or gap junction coupling, may widen the vulnerable window and 
increase the probability of unidirectional block after a premature stimulus 96. Once unidirectional 
block occurs, reentrant tachycardias can occur if the wavelength of excitation, defined as the 
product of CV and effective refractory period (ERP), is shorter than the dimensions of the circuit 
97. Given that slowed conduction velocity in the setting of reduced gap junction coupling can 
predispose to reentrant VT, I performed programmed electrical stimulation on RV and LV of 
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Langendorff-perfused hearts during optical mapping studies. A striking result is that five of seven 
Wnt LOF mice developed VT during RV stimulation at physiologic rates with just a single drive 
train, even without an extrastimulus, while none of the seven littermate controls developed VT in 
the setting of RV pacing (Figure 5.2A-E, Table 5.1). In some instances, a line of functional block 
with reentry on alternating beats occurred on the anterior surface during VT induced by RV 
stimulation. In contrast, the same pacing protocol applied to the LV did not lead to arrhythmias in 
Wnt LOF mice (Table 5.1). Predisposition to arrhythmias can be influenced by factors extrinsic to 
the heart including autonomic tone. To further probe whether Wnt LOF predisposes to an 
arrhythmic substrate in vivo, we performed invasive electrophysiology studies. Wnt LOF mice 
have a shorter RVERP when compared with littermate controls (28±3 vs 38±3 ms, Table 5.1) and 
increased susceptibility to VT following RV programmed electrical stimulation, similar to the 
results observed in ex vivo Langendorff-perfused hearts (Figure 5.2E, Table 5.1). These results 
demonstrate that Wnt transcriptional activity is required for electrical programming of the RV 





Figure 5.2. Wnt loss-of-function mice are predisposed to ventricular tachycardia following 
right ventricular stimulation. Reconstructed electrical activation maps showing the RV surface 
during sinus rhythm (SR, A), RV surface during ventricular tachycardia (VT, B), and anterior view 
of RV and LV during VT (C) from the same Wnt LOF mouse. VT was initiated following 
physiological drive train pacing on the RV epicardium (B) and was persistent. During SR (A) the 
earliest RV breakthrough site is near the apex. VT was initiated by stimulation of the RV 
epicardium with an S1 drive train at 8 Hz. During VT, electrical activation of the ventricles was 
altered both spatially and temporally. Note the different timescales for each activation map, with 
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change in activation pattern from base to apex (B) and focal conduction block with reentry visible 
on the anterior surface during VT (C). (D) Optical action potentials during SR (left) show 1:1 
activation of atria (black, A) followed by ventricle (red, V), whereas there is AV dissociation during 
VT (right) with more ventricular action potentials than atrial. 5 of 7 Wnt LOF (Mlc2vCre/+; 
Ctnnb1dm/flox) and 0 littermate control (Ctnnb1flox/+) hearts exhibited VT following RV stimulation 
while none of the hearts (both Wnt LOF and control) had VT following LV stimulation (Table 5.1) 
(E) Representative EKG (top, green), intracardiac atrial (middle, black) and intracardiac 
ventricular (bottom, red) traces during invasive electrophysiology studies showing an S1 drive 
train at 10 Hz followed by a triple extrastimulus initiating 4 s of polymorphic VT. 4 of 6 Wnt LOF 
and 0 of 6 littermate control mice had VT following RV stimulation (Table 5.1). 
 
 
Figure Contributions: Carla Weinheimer (CW) performed all mouse surgeries. RGL performed 














Chapter 6: Discussion I 
In this study, I show that embryonic programming can differentially regulate adult 
electrophysiology in the right versus left ventricles. I specifically probe a Wnt LOF model where 
β-catenin is transcriptionally inactive but its cell adhesion properties are preserved. Loss of Wnt 
transcriptional activity during development results in a large, yet mostly mutually exclusive, 
number of genes dysregulated in the adult RV and LV. In this Wnt LOF model, CV is preferentially 
slowed in the RV, at least in part due to RV-specific loss of Cx43 (Figure 2.1). Similarly, we 
previously reported that CV is slowed predominantly in the RV in Wnt GOF mice, and I now show 
that the mechanism is through reduced NaV1.5, while Cx43 levels are unchanged (Figure 2.2). 
Previous studies have shown using neonatal rat ventricular myocytes that Wnt activators can 
downregulate both Cx43 and NaV1.5 98, 99. Discrepancies with our Wnt GOF data could perhaps 
be explained by earlier developmental activation in our in vivo model, or modulation of β-catenin 
versus use of a Wnt agonist.  
Interestingly, gap junction remodeling, evidenced by reduced immunostaining for Cx43 at cell-
cell junctions appears to be a consistent feature of arrhythmogenic cardiomyopathy (ACM) 100. 
The classic right-dominant form of ACM, also known as arrhythmogenic right ventricular 
cardiomyopathy, is a leading cause of sudden cardiac death in the young 101. ACM is characterized 
by subepicardial fibro-fatty deposition, and is often associated with mutations in desmosomal 
proteins. ACM patients across a wide etiologic spectrum exhibit altered GSK-3β distribution, and 
pharmacologic inhibition of GSK-3β can rescue both the histologic and electrical phenotypes in 
animal models of the disease 69, 102. Among its diverse functions, GSK-3β regulates the Wnt 
signaling pathway and altered canonical Wnt signaling has been described in animal models and 
in patients with ACM 5, 103-105. ACM patients tend to have prolonged APDs 106, 107, while the 
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RVERP is shorter in Wnt LOF mice (Table 5.1). Therefore, precisely how GSK-3β redistribution 
may impact Wnt signaling, and how Wnt signaling may relate to RV-predominant arrhythmias 
will likely remain an area of active interest. 
Unbiased RNA-sequencing of RV and LV in Wnt LOF mice demonstrates distinct chamber-
specific gene dysregulation, with relatively little overlap (Figure 2.1C). One interesting gene 
regulated by Wnt specifically within the RV is the previously well-studied Notch target Hey2. It 
has long been postulated that regulation of Hey2 expression in the ventricles may not reflect a role 
of Notch signaling, and that Notch-independent mechanisms may also regulate its expression. To 
our knowledge, this is the first study demonstrating Hey2 is a direct Wnt target in any tissue. We 
delineate RV-specific regulation of this gene that has been associated in GWAS studies with 
Brugada syndrome, characterized by sudden death from RV tachycardias 108, 109. Given that recent 
thoughts based on ultrastructural and electrophysiological changes have suggested that perhaps 
Brugada syndrome and ACM represent different spectrums of the same disease 110, it is intriguing 
that Hey2 is transcriptionally regulated by Wnt.  
Differential chamber-specific β-catenin enhancer binding is present by E12.5 (Figure 3.1D), and 
even at this early developmental stage, there is already differential Hey2 enhancer activity (Figure 
3.1E) that coincides with differential β-catenin binding. Increasing β-catenin protein levels from 
early developmental stages when myocytes turn on expression of Myosin light chain 2v onward 
could not overcome differential binding to the Hey2 enhancer (Mlc2vCre; Ctnnb1flox(ex3)/+, Figure 
3.1G). Furthermore, Wnt induction in the adult activates Hey2 transcription only in the RV, while 
transcription of another Wnt target gene, Axin2, is similarly upregulated in both ventricles (Figure 
3.1G). Since Axin2 is upregulated equally in both ventricles, this strongly suggests that the 
mechanism for differential Hey2 levels is not related to the amount of β-catenin in the cell or in 
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the nucleus, but rather points to chamber-specific regulation at the level of active chromatin and 
enhancer binding at specific gene regulatory elements. Furthermore, even though β-catenin protein 
levels in the cell are similar in adulthood, transcriptional differences seen in the adult may result 
from the embryonic programming events that persist. While Hey2 is associated with Brugada 
syndrome and regulates important chamber-specific electrophysiological properties including 
dVm/dtmax 108, previous work has shown that Hey2 does not regulate the maximum upstroke velocity 
through Scn5a transcript levels 88. Therefore, dysregulation of Scn5a and Gja1 by Wnt could also 
occur through direct β-catenin binding to regulatory elements, or through other indirect 
mechanisms. The finding that early embryonic events pattern enhancer binding and regulate 
electrophysiology into adulthood may have implications for protocols involving sequential Wnt-
pathway modulation to derive CMs from induced-pluripotent stem cells for downstream 
applications involving cellular electrophysiology 111. Specifically, a better understanding for the 
differential manner in which Wnt affects many genes relevant to electrophysiology in early right 
versus left ventricular progenitors may provide an opportunity to enhance differentiation and 
maturation of iPS-derived CMs. 
Multiple previous studies have focused on the relationship between gap junction expression and 
arrhythmia susceptibility. Studies on Cx43+/- mice have yielded mixed results 112, 113, and 
cardiomyocyte-specific loss of function studies have shed further light on this relationship 114. 
While reduction of Cx43 protein levels to just under half normal levels did not significantly affect 
LV conduction velocity nor lead to ventricular tachyarrhythmias, further reduction to 18% of 
control levels was associated with decreased LV CV and inducible polymorphic ventricular 
tachycardia 115. Interestingly, though effects on RV CV were not reported in these studies, loss of 
Cx43 had a differential effect on K+ currents in the RV which predisposed to reentrant arrhythmias 
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94. The current study examines the transcriptional role of Wnt signaling on cardiac conduction, 
noting a more robust reduction of Cx43 protein in the RV (approximately 50%, Figure 2.1F) with 
a significant 23% reduction in longitudinal CV (Figure 4.1A,B). Since the degree of RV 
conduction slowing was higher than we expected, we ruled out additional effects on excitability 
(Figure 4.5) or Cx43 protein mis-localization (Figure 4.1C, Figure 4.4). One potential explanation 
for why this degree of Cx43 reduction could lead to marked RV conduction slowing may involve 
distinct safety factors for conduction between ventricles 116. In addition, the RVERP is 
significantly shorter in the Wnt LOF RV (Table 5.1), which would be expected to predispose to 
reentrant tachycardias given a shorter wavelength of excitation. Several genes encoding ion 
channel subunits important in cardiac repolarization are dysregulated in the Wnt LOF RV only 
(NCBI GEO submission GSE106507), including downregulation of genes encoding subunits of 
potassium channels (Kcnn2, Kcnmb1, Kcna4, and Kcnq1). Therefore, additional direct or indirect 
disturbances in ionic currents likely contribute to the marked differential arrhythmogenesis 
observed between the Wnt LOF RV and LV. Although I saw arrhythmia susceptibility in Wnt LOF 
RV in both in vivo and ex vivo experiments (Figure 5.2, Table 5.1), I did not observe spontaneous 
arrhythmias in telemetry-monitored mice injected with isoproterenol (Figure 5.1). This suggests 
that, although Wnt LOF mice have a pro-arrhythmic substrate, they may lack calcium-mediated 
triggers. Consistent with this hypothesis, of the roughly 700 genes and transcripts dysregulated in 
the RV, only one calcium channel gene (Cacna2d3) was dysregulated. 
In the healthy adult heart Wnt signaling is at low levels, but in response to pathologic stimuli such 
as myocardial infarction or pressure overload, Wnt signaling becomes activated 84. Though quite 
a bit is known regarding the effects of Wnt signaling on CM hypertrophy and fibrosis, relatively 
less is known about the effects of Wnt signaling on cardiac conduction and arrhythmogenesis 117. 
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Indeed, therapeutic alteration of Wnt signaling in the post-myocardial infarction setting has 
produced conflicting results 84. Given that aberrant Wnt signaling is associated with diverse 
disorders giving rise to arrhythmias, including acquired disorders such as cardiac hypertrophy and 
myocardial infarction, as well as familial arrhythmias such as ACM, a better understanding of the 




Chapter 7: β-catenin stabilization and acute GSK-3 
inhibition in adult murine cardiomyocytes reduce 
conduction velocity 
GSK-3 dysregulation can occur in the setting of acquired cardiovascular disease in association 
with arrhythmias66, 119. In addition, there have been case reports of associated cardiac arrhythmias 
in patients with neurological disorders that were prescribed the GSK-3 inhibitor lithium68. 
Inhibition of GSK-3 results in β-catenin accumulation and eventual trafficking to the nucleus, 
where canonical Wnt/β-catenin signaling targets can be activated13, 120. Our lab and others have 
previously shown that developmental β-catenin stabilization in mouse cardiomyocytes results in 
downregulation of Scn5a, together with reduced NaV1.5 protein and sodium current density44, 121, 
122. Therefore, I asked whether increased β-catenin in adult cardiomyocytes, which partially 
mimics GSK-3 mediated pharmacologic effects, is pro-arrhythmic. To determine whether cardiac 
conduction is regulated by β-catenin levels, I used a mouse model where we conditionally deleted 
β-catenin exon 3 in cardiomyocytes of adult mice (αMHC-MCM+/o/Ctnnb1fl(ex3)/+, β-catenin GOF), 
which prevents β-catenin degradation through loss of phosphorylation sites targeting the protein 
for ubiquitination. Using optical mapping techniques, I found that electrical activation within 
tamoxifen-induced β-catenin GOF left ventricles is significantly slower when compared to the 
same genotype non-induced control mice (54 cm/s versus 71 cm/s, Figure 7.1A). β-catenin GOF 
hearts were susceptible to both spontaneous and stimulation-induced ventricular tachycardia (5/6 
hearts) while controls were completely free from arrhythmias (0/6 hearts). A representative 
electrical activation map during an episode of ventricular tachycardia shows multiple wavefronts, 
abnormal propagation patterns, and a line of functional block (Figure 7.1B). Conduction velocity 
(CV) was significantly reduced by 15% and 24% in both right and left ventricles of β-catenin GOF 
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hearts, respectively (Figure 7.1C). These results show that increased β-catenin in adult 
cardiomyocytes leads to conduction slowing and subsequent ventricular arrhythmias.  
 
Figure 7.1. Myocyte specific β-catenin gain-of-function and acute GSK-3 inhibition by 
lithium and SB2 reduces conduction velocity in murine hearts. A. Representative activation 
maps showing slowed electrical activation in β-catenin GOF hearts (right) compared to non-
induced controls (left). B. Activation map showing ventricular tachycardia induced from electrical 
stimulation of β-catenin GOF ventricles. The white arrows show irregular propagation of two 
different wave fronts that results in a functional block. Five out of 6 β-catenin GOF and zero out 
6 control hearts had spontaneous or stimulation-induced ventricular tachycardia. C. Conduction 
velocities of right and left ventricles are significantly reduced in β-catenin GOF hearts compared 
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to controls. D. Representative activation maps 3 hours after intraperitoneal injection of lithium 
chloride in wild-type CD1 mice show slower ventricular electrical activation (right) compared to 
vehicle control (left). E. Conduction velocity is decreased by 10% in lithium compared to vehicle 
control injections at 3 hours at all stimulation cycle lengths. F. Action potential duration at 80% 
repolarization is unchanged by lithium injection at all stimulation cycle lengths. G. Representative 
activation maps 24 hours after intraperitoneal injection of SB2 in wild-type CD1 mice shows 
slower ventricular electrical activation (right) compared to vehicle control (left). H. Conduction 
velocity is decreased by 10% in SB2 compared to vehicle control injections at 24 hours at all 
stimulation cycle lengths. I. Action potential duration at 80% repolarization is unchanged by SB2 
injection at all stimulation cycle lengths except at 60 ms, where APD80 is decreased by 10%. 
*p<0.05, **p<0.01.  
 
There is growing evidence for a role of GSK-3 in regulation of cardiac electrophysiology in animal 
models65, 69. Given the effects of increased β-catenin on cardiac conduction, I asked whether 
inhibition of GSK-3, which stabilizes β-catenin, can also reduce conduction velocity. To determine 
whether GSK-3 inhibition can acutely alter cardiac conduction, I intraperitoneally injected lithium 
into wild-type mice and assayed conduction velocity (CV) via optical mapping 3 hours after 
injection. I found that CV was decreased 13% in hearts of lithium-injected mice compared to 
vehicle control for all stimulation cycle lengths (62 cm/s versus 71 cm/s at 125 ms cycle length, 
Figure 7.1D,E), while action potential duration at 80% repolarization (APD80) was unchanged 
(Figure 7.1F). Since there is evidence that lithium can inhibit sodium current through competition 
with sodium ions independent of GSK-3 inhibition123, I also tested SB2, which is a more specific 
inhibitor of GSK-3. Given the solubility differences between lithium and SB2, I measured the 
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effects of SB2 one day after injection. Similar to what I observed with lithium, acute SB2 treatment 
resulted in a 10% decrease in CV at all cycle lengths compared to vehicle control (62 cm/s versus 
69 cm/s at 125 ms cycle length, Figure 7.1G,H), and APD80 was unchanged at most stimulation 
cycle lengths, except 60 ms where APD80 was decreased by 10% (Figure 7.1I). While lithium 
inhibits GSK-3 through competition for magnesium, SB2 is an ATP-competitive inhibitor of GSK-
3124, 125. Therefore, the fact that CV is similarly reduced by two different compounds which inhibit 
GSK-3 through distinct mechanisms suggests there is a class effect of GSK-3 inhibitors on cardiac 
electrophysiology. 
 




Chapter 8: Acute GSK-3 inhibition increases 
chromatin-bound β-catenin in human myocardium 
Inhibition of GSK-3 has been shown to reduce phosphorylation of β-catenin, thereby stabilizing 
the protein and allowing its accumulation. To determine whether SB2 can acutely lead to increased 
β-catenin levels in the adult human heart, I cultured human organotypic slices from the LV of non-
failing donor hearts. Compared to time zero (baseline) and 3 hour control (vehicle only), slices 
cultured in SB2 for 3 hours showed a 31% increase in β-catenin protein (Figure 8.1A). β-catenin 
is known to localize within the cytoplasm, nucleus, and at intercalated discs. Therefore, to further 
investigate how different pools of β-catenin are affected by treatment with SB2, I fractionated 
proteins from human slices into cytoplasmic, membrane-bound, soluble nuclear, and chromatin-
bound nuclear pools. Within the cytoplasm, membrane fraction, and soluble nuclear fraction, β-
catenin levels were not significantly changed after 3 hours in culture between control and SB2 
slices (Figure 8.1B-D). In contrast, overall β-catenin as well as the non-phosphorylated active form 
of β-catenin, were both significantly increased in the chromatin-bound fraction, suggesting that 
acute GSK-3 inhibition by SB2 results in β-catenin translocation into the nucleus (Figure 8.1E). 
Surprisingly, in addition to a band at 92 kDa, the β-catenin in the chromatin-bound fraction had 
multiple bands of lower molecular weights compared with the other sub-cellular fractions. This 
result is consistent with studies in other cell types that have shown truncated forms of β-catenin 




Figure 8.1. Acute SB2 treatment increases β-catenin protein in human left ventricular slices. 
A. Western blot of β-catenin and GAPDH levels with quantification based on band density relative 
to GAPDH shows an increase in β-catenin (31% average increase) in SB2-treated slices. Western 
blot of cytoplasmic β-catenin with respect to GAPDH (B), membrane β-catenin with respect to 
NaK-ATPase (C), and nuclear soluble β-catenin with respect to lamin A/C (D) were unchanged 
between 3 hour control slices and slices cultured with SB2 for 3 hours. E. Both chromatin-bound 
β-catenin and non-phosphorylated β-catenin levels increased with respect to Histone H3 in slices 
cultured with SB2. In contrast to other subcellular fractions, Chromatin-bound β-catenin shows 




To further confirm the cell fractionation findings, I used immunofluorescence to determine 
whether active β-catenin (ABC, phospho-Y489-β-catenin described as nuclear bound129) localizes 
within cardiomyocyte nuclei by assessing co-localization with the myocyte nuclei marker 
pericentriolar material 1 (PCM1). In all conditions, many myocyte nuclei are positive for ABC 
staining, while there are few to no PCM1-negative, non-cardiomyocyte nuclei positive for ABC 
(Figure 8.2A). Taken together with the increased chromatin-bound β-catenin seen after SB2 
treatment (Figure 8.1), these results suggest that β-catenin is increased within the cardiomyocyte 
nuclei of SB2-cultured slices. Despite the increased chromatin-bound β-catenin, we were surprised 
to find that the canonical Wnt/β-catenin target genes TCF7L2, LEF1, and AXIN2 were unchanged 
in SB2-treated slices compared to 3 hour vehicle control cultured slices (Figure 8.2B). β-catenin 
presence in the nucleus is tightly regulated, and prior to this study thought to be scarcely detected 
in healthy hearts where Wnt/β-catenin signaling is quiescent. However, I show here that significant 
amounts of chromatin-bound β-catenin exist in adult human hearts at baseline, with increased 
nuclear β-catenin levels seen in response to acute GSK-3 inhibition without concomitant activation 




Figure 8.2. Nuclear active β-catenin (ABC) is present at baseline and increases with SB2 
without activating Wnt/β-catenin target genes. A. ABC (green) is present in human myocyte 
nuclei, marked by PCM1 (red) and DAPI (blue), in baseline, 3 hour control, and 3 hour SB2 
conditions. White arrowheads indicate β-catenin-positive cardiomyocyte nuclei while white 
asterisks mark β-catenin-negative cardiomyocyte nuclei. B. Transcription of Wnt/β-catenin target 
genes (TCF7L2, LEF1, and AXIN2) and negative control (ACTC1) are unchanged by SB2 at 3 




Figure Contributions: RGL performed all Western blots and immunofluorescence experiments. 
















Chapter 9: GSK-3 inhibition reduces conduction 
velocity and action potential excitability in human 
myocardium 
To determine whether acute GSK-3 inhibition has a similar effect on cardiac conduction in the 
human heart as in mouse models, we performed optical mapping on human organotypic slices at 
baseline (0 hour), and after culture with either control (DMSO vehicle) or SB2. To minimize 
potential variability between hearts and between different regions within the same heart, adjacent 
slices were used for control and drug treatment. Importantly, CV remained unchanged between 
baseline and 24 hour control slices (Figure 9.1), suggesting that our culture technique preserves 
human cardiac electrophysiology. Compared to baseline, CV did not change 15 minutes after 
addition of SB2 into the physiologic bath (data not shown). In contrast, CV was decreased after 
24 hours in culture with SB2 when compared to baseline, and to adjacent slices from the same 
heart cultured with vehicle for 24 hours (Baseline: 61 cm/s, 24Hr: 60 cm/s, 24Hr SB2: 47 cm/s), 
and this decrease persisted at different stimulation cycle lengths (Figure 9.1A,B). CV restitution 
plots from control and SB2-treated slices from each individual heart shows similar decreases in 




Figure 9.1. Conduction velocity of human LV slices is reduced after 24 hours of SB2 treatment. 
A. Representative activation maps of a control slice (left) compared to a SB2-treated slice (right) 
from the same heart. Squares in the top panels indicate regions of the activation maps zoomed-in 
(bottom) to further demonstrate slower activation in the SB2-treated slice as seen by the greater 
number of isochrones to reach the same distance. B. Conduction velocity quantified from 
activation maps show no difference between baseline and 24 hour control, but ~23% reduced 
conduction velocity in 24 hour SB2-treated slices at pacing cycle lengths of 1000 ms, 800 ms, and 
600 ms. C. Conduction velocity restitution of adjacent slices from each individual heart, indicated 
by different colors, shows reduced conduction velocity at all stimulation cycle lengths but no 
change in restitution slope in SB2-treated slices. Statistics were performed using repeated 





We empirically determined that 3 hours was the most acute time point where SB2 is observed to 
have an effect on CV. Similar to the 24 hour time point, CV was decreased in SB2-cultured slices 
when compared to baseline and 3 hour controls. A representative activation map shows slower 
electrical activation and action potential propagation in SB2 cultured slice compared with 3 hour 
control (Figure 9.2A,B). CV of SB2 cultured slices was slower by 18% compared to 0 hour and 3 
hour control (Baseline: 62 cm/s, 3Hr: 63 cm/s, 3Hr SB2: 51 cm/s at 1000 ms cycle length) across 
all stimulation cycle lengths (Figure 9.2C). CV restitution of control and SB2-treated slices for 
each individual heart showed similar magnitude of decrease in CV and no change in restitution 
slope (Figure 9.2D). Since CV was reduced at 3 and 24 hours in culture with SB2 but not 15 
minutes, SB2 is unlikely to have an immediate effect on ionic conductances leading to reduced 
CV, and likely acts through cell signaling processes. 
 
Figure 9.2. Conduction velocity of human LV slices is reduced by short term culture with 
SB2. A. Representative activation maps of a control slice (left) compared to a SB2-treated slice 
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(right) from the same heart. Electrical activation from time t0 to t1 is slower in the SB2-treated slice 
as seen by the greater number of isochrones to reach the same distance. B. Control optical action 
potentials (top) at t0 (blue) and t1 (dashed cyan) shows faster propagation compared to SB2 optical 
action potentials (bottom) from t0 (red) to t1 (dashed magenta). C. Conduction velocity quantified 
from activation maps show no difference between baseline and 3 hour control, but reduced 
conduction velocity in 3 hour SB2-treated slices (Baseline: 62 cm/s, 3Hr Control: 63 cm/s, 3Hr 
SB2: 51 cm/s) at pacing cycle lengths of 1000 ms, 800 ms, 600 ms, and 400 ms. D. Conduction 
velocity restitution of each individual heart shows reduced conduction velocity at all stimulation 
cycle lengths but no change in restitution slope in SB2-treated slices. Each color represents an 
individual heart for 3 hour vehicle (solid line) or 3 hour SB2 (dashed). Statistics were performed 
using repeated measures ANOVA followed by a post-hoc Tukey’s multiple comparisons test.  
*p<0.05, ns = not significant. 
 
To determine more precisely how acute application of SB2 affects cardiac action potentials in a 
manner that is expected to lead to CV slowing, we performed sharp microelectrode recordings on 
human organotypic slices. Representative averaged action potentials of slices paced at 1000 ms 
from a human heart show overall similar action potential morphology for 0 hour, 3 hours in culture, 
and 3 hours in culture with SB2 (Figure 9.3A,B). A magnified view to allow for closer inspection 
of the averaged action potential upstroke reveals that the maximum upstroke velocity, dVm/dtmax, 
is decreased in SB2 cultured slices (Figure 9.3C), and this reduction was observed in SB2-treated 
slices from each individual heart (Figure 9.4). While the resting membrane potential (RMP), action 
potential amplitude (APA), and action potential duration at 90% repolarization (APD90) were 
unchanged between all conditions, dVm/dtmax was decreased by 22% (250 V/s in vehicle control 
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versus 195 V/s in SB2-treated slices, Figure 9.3D-G). One major determinant regulating cardiac 
CV is sodium current density and kinetics. Maximum upstroke velocity of action potentials have 
been shown to be a direct surrogate of maximum sodium current density and/or channel 
activation/inactivation130. Therefore, the observed decrease in dVm/dtmax due to SB2 suggests a 
decrease in sodium current density and/or a leftward shift in channel inactivation contributing to 




Figure 9.3. Action potential upstroke velocity is decreased in SB2-treated slices. A. 
Representative action potentials from control without culture (blue), 3 hour cultured (magenta), 
and 3 hour SB2 cultured (red) slices paced at a cycle length of 1000 ms. B. Averaged action 
potential of all recorded myocytes from slices for each condition. C. (Top) Zoom of action 
potential upstroke from B shows decreased dVm/dtmax in SB2-treated slices compared to control 
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and 3 hour cultured control (Baseline: 234.1 V/s, 3Hr Control: 249.7 V/s, 3Hr SB2: 195.4 V/s). 
Action potential upstroke change in membrane potential (ΔVm, bottom) over the same time period 
shows significant decrease in dVm/dtmax for SB2-treatment and not a decrease for the entire duration. 
D-G. RMP, APA, APD90, and APD restitution are not changed between all conditions for each 
individual heart, while dVm/dtmax is significantly decreased in action potentials from slices cultured 
with SB2 compared with control and cultured control. Statistics were performed using repeated 
measures ANOVA followed by a post-hoc Tukey’s multiple comparisons test.  
 
 
Figure 9.4. SB2 treatment decreases maximum action potential upstroke velocity at 3 hours in 
culture. Averaged action potentials from slices paced at a cycle length of 1000 ms shows a decrease 
in dVm/dtmax in each individual heart when cultured with SB2. Each column represents an 
individual heart, with the top panels showing averaged action potentials of 3 hour control (blue) 





Figure Contributions: RGL and David Zhang (DZ) performed all optical mapping experiments. 
















Chapter 10: Acute GSK-3 inhibition results in 
decreased NaV1.5 independent of Wnt transcription 
To determine whether reduced sodium channel conductance can account for the magnitude of 
conduction slowing, our collaborator Dr. Patrick Boyle carried out simulations in a virtual 
organotypic slice. Conductivity tensor values were calibrated to match experimental CV 
observations (longitudinal: σL = 0.234 S/m, and transverse: σT = 0.0176 S/m); all other input 
parameters were unchanged from published versions, as described in Materials and methods 
(Chapter 12). At baseline, all output parameters predicted by the model at various stimulation cycle 
lengths matched well with experimentally measured values (Figure 10.1A-E; e.g., at 1000 ms basic 
cycle length, CV = 67 cm/s; APD90 = 350 ms, dV/dtmax = 232 V/s). Therefore, we are confident 




Figure 10.1. Computational simulations conducted in virtual cardiac organotypic slices 
accurately reproduce experimental electrophysiological data. A. Activation sequence in 
response pacing at a basic cycle length (BCL) of 1000 ms (top); membrane voltage over time at 
points indicated in top panel (bottom). B. Same as A but for excitation in response to a stimulus 
(S2) delivered 400 ms later. C. Longitudinal conduction velocity (CV) restitution relationship 
shows reasonable correspondence between simulations (white squares) and experiments (black 
circles) at all S1-S2 intervals. D-E. Adaptation relationships for upstroke velocity (dV/dtmax) (D) 
and 90% action potential duration (APD90) (E) show that the model reproduces values seen in 





Both CV and dV/dtmax are influenced by sodium channel conductance (GNa) and sodium channel 
kinetics (e.g., shifts in voltage-dependent activation/inactivation) 131. Therefore, we first asked if 
changes in one or both of these parameters might explain our experimental observations. Using a 
bisection approach, we found that an 18% CV reduction (as observed experimentally) could be 
elicited in the model by either a 53.6% GNa decrease or a –8.14 mV shift in INa inactivation kinetics; 
however, both of these changes resulted in a much more dramatic dV/dtmax reduction than we 
observed ex vivo (rows 1-2 of Table 10.1). Likewise, adjusting GNa and INa inactivation shift to 
different values (19.2% and –3.14 mV, respectively) produced better agreement with upstroke 
velocity behavior seen ex vivo, but this resulted in divergent CV behavior (rows 3-4 of Table 10.1). 
Therefore, neither decreased GNa nor shifted INa inactivation kinetics can fully account for 
observed drug effects in experimental data. In contrast, when we examined effects of either input 
in conjunction with reduced tissue conductivity (σi), we found combinations that gave rise to 
simulations with reductions in CV and dV/dtmax that closely matched those seen ex vivo (rows 5-6 
of Table 10.1). 
Table 10.1. Summary of simulation results in models with selected combinations of reduced 
sodium channel conductance (GNa), shifted sodium current (INa) inactivation curve; and reduced 
intracellular conductivity (σi). Rows 1-4 show that neither GNa reduction nor shifted INa 
inactivation kinetics can fully explain the experimentally observed changes in CV and dV/dtmax. 
In contrast, when either of the two parameters is reduced in combination with σi reduction (rows 
5-6), model behavior closely matching experiments is observed. Green highlights = close match 






 Parameters Modified to 
Match Ex Vivo CV and 
dV/dtmax   





shift σi reduction CV dV/dtmax  
1 53.60% n/a n/a −0.63% −40.64% 
2 n/a −8.14 n/a −0.63% −40.19% 
3 19.20% n/a n/a 28.42% −0.05% 
4 n/a −3.14 n/a 28.42% −0.50% 
5 25.00% n/a 40.00% −0.63% 1.13% 
6 n/a −4.00 40.00% −0.63% 0.59% 
 
 
To gain further insight into the underlying molecular mechanism(s) for the observed decrease in 
CV and dVm/dtmax revealed through computational modeling, we performed RT-qPCR and Western 
blotting to determine expression of relevant transcripts and proteins. First we asked whether 
expression of genes regulating conduction velocity, including SCN5A and GJA1, which encode for 
NaV1.5 and Cx43, respectively, and FGF12, the human homolog of mouse Fgf13 that encodes for 
fibroblast growth factor 13 and has previously shown to directly modulate sodium current 
density132, are altered by acute GSK-3 inhibition. None of these genes (SCN5A, GJA1, FGF12) 
have altered expression in the human organotypic slices cultured with SB2 at 3 hours compared to 
3 hour controls (Figure 10.2A). Next, I analyzed protein abundance of Cx43, the major ventricular 
connexin responsible for cell-to-cell electrical coupling. In addition to total amounts, 
phosphorylated isoforms of Cx43 have been shown to be involved in altered intercellular 
communication and influence gap junction assembly92. Phosphorylation of Cx43 at serine 368 
results in Cx43 mis-localization and reduced channel conductance133, 134. Cx43 total amounts were 
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not significantly changed between the different conditions (Figure 10.2B), and additionally I found 
no difference in Cx43 phosphorylated at serine 368 between baseline, 3 hour control, and 3 hour 
SB2 by Western blot (data not shown). Consistent with the Western blot results, through 
immunohistologic techniques I found that Cx43 is primarily localized at intercalated discs and 
there are no major differences in Cx43 localization between baseline, 3 hour control, and 3 hour 
SB2 (Figure 10.3A-C). Therefore, the observed reduction in CV due to tissue conductivity is not 
likely due to changes in Cx43 protein amount, serine 368 phosphorylation, or localization. 
 
Figure 10.2. Short term SB2 culture of LV slices results in changes in NaV1.5 protein but not 
gene transcription. A. RT-qPCR shows no changes between 3 hour in culture and 3 hour in 
culture with SB2 for ACTC1 (negative control), electrophysiology related transcripts (SCN5A, 
GJA1), and FGF12, a known regulator of cardiac sodium current. B. Western blot for Cx43 and 
GAPDH shows no significant changes between Cx43 relative to GAPDH for all conditions. C. 
Western blot for NaV1.5 and GAPDH with quantification based on band density relative to 
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GAPDH shows a decrease in NaV1.5 protein (30% average decrease) in SB2 condition compared 
to 3 hour control. ns = not significant. Statistics were performed using repeated measures ANOVA 
followed by a post-hoc Tukey’s multiple comparisons test.  
 
 
Figure 10.3. Cx43 and NaV1.5 localization is unchanged by GSK-3 inhibition via SB2. DAPI 
(blue) and Cx43 (red) in baseline (A), 3 hours in culture (B), and 3 hours in culture with SB2 (C) 
shows no gross differences or Cx43 lateralization. DAPI (blue) and NaV1.5 (red) in baseline (D), 
3 hours in culture (E), and 3 hours in culture with SB2 (F) shows no differences in general structure 
or NaV1.5 localization. Scale = 20 μm.  
 
Given reduced dVm/dtmax in SB2-cultured cardiac slices, I examined sodium channel protein 
abundance and found that NaV1.5 was decreased by 30% after SB2 treatment when compared to 
control slices (Figure 10.2C). In addition to reduced total protein amounts, mis-localization of 
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NaV1.5 could also contribute to CV decreases. Immunostaining revealed that NaV1.5 is localized 
to the intercalated discs and sarcolemma, with no major differences between localization between 
baseline, 3 hour control, and 3 hour SB2 (Figure 10.3D-F). These results suggest that CV slowing 
and reduced action potential upstrokes are, at least partially, due to decreased Nav1.5 protein and 
reduced sodium conductance. Taken together, although there is increased chromatin-bound β-
catenin (Figure 8.1E) and decreased NaV1.5, the lack of concomitant changes in SNC5a transcript 
suggest that GSK-3 inhibition reduced CV, at least in part, through mechanisms independent of 
canonical Wnt signaling. 
 
Figure Contributions: Patrick Boyle (PB) performed all computational simulations. RGL and 
KTY performed all immunofluorescence experiments. RGL performed all Western blot 














Chapter 11: Discussion II 
GSK-3 inhibition has recently emerged as a potential therapy for a broad spectrum of diseases, 
ranging from cancer to diabetes to Alzheimer’s disease55, 61, 135. In the heart, studies involving 
conditional deletion of GSK-3 in mouse models have provided additional evidence that inhibition 
of GSK-3 can be cardioprotective in settings of myocardial infarction and ischemia64, 136. However, 
the precise effects of GSK-3 inhibition in the adult human heart with respect to cardiac 
electrophysiology remain undefined. Recent evidence implicating GSK-3 in regulation of cellular 
electrophysiology led me to examine the effects of GSK-3 inhibition on cardiac electrophysiology 
in the human heart. The ability to measure electrophysiology in 3D cardiac tissue engineered 
platforms have been important in studying drug effects and heritable arrhythmias137, 138. This study 
used organotypic slice culture as a platform for accessing the physiological response of the human 
heart to acute GSK-3 inhibition. The unique advantage of the slice culture model for investigating 
cardiac electrophysiology and molecular mechanism over isolated cardiomyocytes and induced 
pluripotent stem cell-derived tissues is having a mature, 3-dimensional multicellular model with 
intercellular connections. I show for the first time the effects of GSK-3 inhibition on human cardiac 
tissue electrophysiology, and an acute time point of 3 hours is sufficient to reduce CV and action 
potential excitability. Finally, via analysis of simulations conducted in virtual organotypic slices, 
we formulate and subsequently test the hypothesis that reduced sodium channel expression 
underlies this effect. 
GSK-3 is well known to regulate many different ion channels, and specifically, GSK-3β regulates 
various calcium, chloride, sodium, and potassium ion channels in the nervous system139. A study 
in adrenal chromaffin cells showed that, in addition to regulating GSK-3, lithium may also directly 
inhibit sodium channel function123. Conflicting evidence exists on the effects of GSK-3 inhibition 
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on cardiac electrophysiology. Lithium-induced pro-arrhythmic effects have been described to 
occur through dosage dependent block of peak sodium current68. In this study, I utilized a specific 
inhibitor of GSK-3, namely SB2, and demonstrated that acute GSK-3 inhibition slows CV in wild-
type mice and in tissue slices from non-failing human hearts. Additionally, I demonstrated that 
SB2 reduced maximum action potential upstroke velocity and NaV1.5 protein in human cardiac 
tissue. In contrast to these findings, other studies have found SB2 can be beneficial in treating 
cardiomyopathy progression in cell lines, as well as in murine and zebrafish models of 
arrhythmogenic cardiomyopathy (ACM), through trafficking-mediated reversal of mis-
localization of membrane proteins including Cx43 and NaV1.565, 69. Multiple factors could possibly 
account for the differences we observed, including differences in model platform used (normal 
versus disease tissue), and importantly the drug dosages and time points of analysis. In our studies, 
we used adult human organotypic slices from non-failing donor hearts without gross structural 
phenotypes, whereas other studies used cell lines, zebrafish, and mouse hearts with desmosomal 
protein mutations that lead to severe structural remodeling. The dosage and chronicity of SB2 used 
in our human slices also differed from previous animal studies, with an acute application (3 hours 
in culture vs. weeks of daily intraperitoneal injection) and much lower dosage (10 times IC50 vs. 
2.5 mg/kg). Additionally, GSK-3β was shown to be elevated in both mouse and human patient 
samples of ACM but not in other cardiovascular pathologies65. Therefore, it is possible that the 
effects of SB2 may depend on initial levels of GSK-3 activity, and inhibition of hyperactivity 
versus homeostatic levels may yield different outcomes. 
Overall β-catenin levels within the cell increased acutely after GSK-3 inhibition. While membrane-
associated β-catenin increased in two of three human hearts (Figure 8.1C), this result was not 
statistically significant and only the chromatin-bound β-catenin reliably increased in each heart 
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(Figure 8.1E). As a tightly regulated transcriptional co-factor, β-catenin localization to the nucleus 
is typically thought to be associated with transcriptional changes. While acute GSK-3 inhibition 
increased nuclear β-catenin at the timepoint when CV slowing occurs, transcription of SCN5A, 
GJA1, and select Wnt/β-catenin target genes was not changed. These results suggest there is also 
a transcriptional-independent mechanism for the observed reduction in NaV1.5 at this acute 
timepoint. In β-catenin GOF mice where a similar CV reduction is seen at later timepoints, 
decreased NaV1.5 protein is associated with downregulation of Scn5a transcript121. Therefore, it is 
likely that other transcriptional or post-translational processes are triggered through increased β-
catenin, such as phosphorylation, SUMOylation, and ubiquitination of NaV1.5140, 141, and may 
work in parallel with transcriptional regulation to inhibit sodium channel conductance. Indeed, it 
is often the case that cell signaling pathways amplify an initial signal, acting at multiple points 
downstream to inhibit cellular processes. In addition, increased nuclear β-catenin may regulate 
transcription of genes not assayed here. Interestingly, I found that β-catenin exists in the nucleus 
at baseline, and multiple β-catenin isoforms of varying molecular weights are bound to chromatin 
and are not present in other cellular fractions. Consistent with our data presented here, a recent 
study showed chromatin-bound β-catenin exists in a repressive complex with GATA4 in 
cardiomyocytes at baseline, and only in the presence of pathologic stimuli does β-catenin become 
transcriptionally active142. Therefore, whether the increase in chromatin-bound β-catenin and/or 
different β-catenin isoforms observed in the nucleus have significance in gene regulation in the 
adult human heart remains an area of future investigation. 
Computational modeling showed strong agreement with our experimental data. I observed an 
average of 30% decrease in NaV1.5 protein in human tissue slices cultured with SB2 ex vivo, which 
could account for at least the magnitude of decrease in dVm/dtmax but would fall short of the 
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observed reduction in CV. Simulation showed that σi must be decreased by 40% in conjunction 
with 25% GNa decrease to fully recapitulate the experimentally-observed behavior. Simulations 
showed that σi reduction combined with a modest negative shift in INa channel inactivation kinetics 
could also explain the particular combination of dVm/dtmax and CV decrease we saw ex vivo, but 
overall the reduced NaV1.5 protein is most consistent with GNa decrease. Finally, it is noteworthy 
that, aside from a single calibration step (i.e., adjustment of baseline σi values to match CV), our 
model consists entirely of previously published formulations that were derived independent of the 
present experimental data. As such, we find it quite reassuring that our virtual organotypic slices 
accurately recapitulated complex electrophysiological relationships (APD90 and upstroke velocity 
adaptation). We are thus optimistic that this computational platform could be used in future studies 
to test (and generate) mechanistic hypotheses for future work in this field. 
Overall, this study utilizes human organotypic ventricular slices as a robust preclinical platform 
for studying the effects of drugs on human electrophysiology. We demonstrate that GSK-3 
inhibition acutely affects human cardiac electrophysiology in a pro-arrhythmic manner, partially 
through NaV1.5 downregulation in a mechanism independent of direct Wnt/β-catenin transcription. 
Our study expands the collective understanding of how GSK-3 inhibitors may increase 
arrhythmogenic potential in patients and, taken together with clinical case reports68, may warrant 
frequent monitoring for possible pro-arrhythmic effects in clinical trials targeting therapeutic 





Chapter 12: Materials and methods 
Human Tissue Acquisition 
Non-failing donor hearts rejected from transplantation were obtained from Mid-America 
Transplant Services in St. Louis, MO. Informed consent was obtained by Mid-America Transplant 
Services for all tissue used in this study. Experimental protocols were approved by the Washington 
University in St. Louis Institutional Review Board, and are in accordance with all research 
guidelines on human tissue. Living donor hearts were procured by an experienced cardiothoracic 
surgeon, perfused and transported to the research lab while in Belzer UW Cold Storage Solution 
(Bridge to Life).  
Slice Preparation 
Heart samples were processed within 30 minutes of procurement. A 1cm by 1cm cube of left 
ventricular tissue was cut in UW solution from a region near the left anterior descending artery 
and circumflex artery. Premade, cooled 4% agarose gel was glued to the tissue holder of a vibrating 
microtome (7000 smz-2, Campden Instruments) and the tissue cube was mounted, endocardium 
up, using Histoacryl glue (B. Braun). Slices were cut tangential to the endocardium with a 
thickness of 400 μm at a rate of 0.04 cm/s, in a 4oC bath of modified Tyrode’s solution with 
excitation contraction uncoupler BMD (2,3-butanedione monoxime) (NaCl 140mM, KCl 6mM, 
glucose 10mM, HEPES 10mM, MgCl2 1mM, CaCl2 1.8mM, BDM 10mM, pH 7.4) supplied with 
100% oxygen. 
Slice Culture  
Slices were cultured on porous transwell inserts (PICM0RG50, Millipore) in 6-well culture plates 
with 1.1 ml of culturing medium (medium 199 (M4530, Sigma) supplemented with 1% penicillin-
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streptomycin (15140163, ThermoFisher), 1X insulin-transferrin-selenium supplement (41400045, 
ThermoFisher), and 10 mM BDM each. Culture plates were placed in a 37oC incubator with 
humidified air and 5% CO2 for 3 or 24 hours before slices were used for electrophysiology or 
saved for histology, gene expression, and protein. SB216763 (SB2), an adenosine triphosphate 
(ATP)-competitive inhibitor of GSK-3, was added to culture media to reach a concentration of 343 
nM, 10 times the IC50 reported in cell-free assays. DMSO was used as vehicle control. Adjacent 
slices from the same heart was used as controls to minimize endo to epi and heart to heart 
variability.  
Mice 
Mlc2vCre/+ 143, αMHC-Cre 144, αMHCrtTA 145, Ctnnb1dm 79, Ctnnb1flox 146, Ctnnb1fl(ex3) 147, TetO-
Cre 148 alleles were used to generate developmental Wnt LOF (Mlc2vCre/+; Ctnnb1dm/flox), 
developmental Wnt GOF (Mlc2vCre/+; Ctnnb1fl(ex3)/+ or αMHC-Cre; Ctnnb1fl(ex3)/+), and inducible 
Wnt GOF (αMHCrtTA; TetO-Cre; Ctnnb1fl(ex3)/+). To characterize Wnt signaling activity at 
different time points, Tcf/Lef:H2B-GFP embryos and mice were used 86. Animals were maintained 
on a mixed genetic background. Animal protocols were approved by the Animal Studies 
Committee at Washington University, and animals were handled in accordance with the NIH 
Guide for the Care and Use of Laboratory Animals. Control data for molecular biology and 
electrophysiology were obtained from littermate animals with genotypes: Ctnnb1flox/+ for Wnt LOF, 
Ctnnb1fl(ex3)/+ for Wnt GOF, and TetO-Cre; Ctnnb1fl(ex3)/+ for inducible Wnt GOF (iWnt). Mice of 
both sexes were used in all studies, and though experiments were not powered to specifically detect 





Mouse Genotype Phenotype 
Wnt GOF Mlc2vCre/+;Ctnnb1fl(ex3)/+ Survives to adulthood 
Wnt GOF αMHC-Cre; 
Ctnnb1fl(ex3)/+ 
Embryonic lethal 44 
Wnt GOF αMHCrtTA; TetO-Cre; 
Ctnnb1fl(ex3)/+ 
Adult Inducible, survives to 
adulthood 
Wnt LOF Mlc2vCre/+; Ctnnb1dm/flox Survives to adulthood 
Wnt Reporter Tcf/Lef:H2B-GFP Survives to adulthood (no 
overt phenotype) 
 
The inducible cardiomyocyte-specific β-catenin gain-of-function (GOF) mouse model was made 
by combining mice expressing MerCreMer under control of the α-myosin heavy chain promoter 
(αMHC-MCM149) with Ctnnb1fl(ex3) 80. Cardiomyocyte-specific expression of Cre recombinase was 
induced by administration of tamoxifen chow (Teklad) for 10 days in 8-week old mice. Excision 
of β-catenin exon 3 results in stabilized, non-degradable β-catenin. A wash-out period of 4 weeks 
following induction was used to allow recovery from the possibility of tamoxifen-related 
cardiomyopathy150. Littermate control mice treated with tamoxifen or αMHC-
MCM+/o/Ctnnb1fl(ex3)/+ without induction were used as controls. 
Wild-type adult littermate CD-1 mice (Charles River) were intraperitoneally injected with SB2 or 
lithium chloride. SB2 was reconstituted in DMSO and further diluted in sunflower oil to be 
delivered at a dosage of 2.5 mg/kg (~7 μM). Control mice were injected with DMSO and sunflower 
oil. Hearts were harvested for tissue or electrophysiology studies 24 hours post injection. Lithium 
chloride was diluted in water and injected at a dosage of 400 mg/kg (~70 mM). Control mice were 
injected with saline. Hearts were harvested for tissue or electrophysiology studies 3 hours post 
injection. The difference in time points for studies post injection is due to differences in solubility 
of lithium and SB2, with presumed faster intake of water-soluble lithium compared to DMSO-
soluble SB2. Equal numbers of male and female mice were used for all experiments. Animal 
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protocols were approved by the Animal Studies Committee at Washington University, and animals 
were handled in accordance with the NIH Guide for the Care and Use of Laboratory Animals. 
Optical Mapping  
Changes in the membrane potential of human ventricular slices and murine Langendorff perfused 
hearts were recorded using optical mapping described previously151, 152. Slices were superfused 
with modified Tyrode’s solution (NaCl 140mM, KCl 4.5mM, glucose 10mM, HEPES 10mM, 
MgCl2 1mM, CaCl2 1.8mM, pH 7.4) at 37°C, while murine hearts were perfused with a different 
modified Tyrode’s solution (NaCl 128.2 mM, KCl, 4.7 mM, glucose 11.1 mM, NaH2PO4 1.19 mM, 
NaHCO3 20 mM, MgCl2 1.05 mM, CaCl 1.3 mM, pH 7.4) at 37°C. Blebbistatin (Cayman 
Chemical), an excitation-contraction uncoupler, was used to eliminate motion artifacts in the 
recorded optical signals. Changes in the membrane potential were detected by Di-4-ANEPPS (Life 
Technologies), a voltage-sensitive dye. A green LED light source with the wavelengths of 520 ± 
5 nm was used to excite the voltage-sensitive dye. The emitted fluorescence was filtered by a long-
pass filter at 650 nm and collected by the CMOS camera (SciMedia). The recorded data were 
analyzed using an open source custom MATLAB program. Human ventricular slices and murine 
hearts were electrically stimulated at different cycle lengths to obtain adaptation and restitution 
curves, with the stimulus amplitude being twice the capture threshold with a pulse duration of 2 
ms. Using surface coordinates and time of the maximum derivatives (dVm/dtmax) of the optical 
signals, activation maps were generated and used to calculate the conduction velocity (CV). 
Longitudinal conduction velocity was calculated by distance traveled over the number of time 
isochrones along multiple lines originating from the site of stimulation. Investigators were blinded 





Microelectrode recordings were obtained from slices of human hearts at baseline, 3 hours in culture 
with DMSO (vehicle control), and 3 hours in culture with SB2. Mouse hearts were Langendorff 
perfused and were recorded while in sinus rhythm. Using glass sharp microelectrodes, single RV 
or LV CMs were sampled near the epicardial surface. Thin glass pipettes with high resistance (10-
20 MΩ) filled with 3M KCl were used to record action potentials from a minimum of 8 single cells 
from different regions of each slice/heart (technical replicates). To decrease noise from motion 
artifacts, blebbistatin was used to arrest motion and allow for stable microelectrode recording 
without requiring the use of floating electrodes. Electrical signals were digitized by a Power 1401 
A/D converter. Action potential of sampled cells with a resting membrane potential (RMP) less 
than -75mV were averaged. The RMP, action potential amplitude (APA), maximum upstroke 
velocity (dVm/dtmax), and action potential duration (APD) at 90% repolarization are reported. 
Analysis of microelectrode recordings was performed using a custom MATLAB script. Cells with 
at least 20 action potentials and stable RMP were included in the data analysis. For each action 
potential in each cell, the peak potential value and time were calculated. The RMP was then 
calculated for each action potential using a histogram, where the maximum frequency value was 
defined as the RMP. The magnitude (amplitude) of each action potential was then defined as the 
difference between peak potential value and the RMP. The maximum change in voltage with 
respect to time (dVm/dtmax) was calculated using a first derivative. The point in time that 
corresponds to this value was then used as the start time for APD calculation. The end time was 
when the membrane potential decreased to 10% of the amplitude value. Investigators were blinded 




Intracardiac Electrophysiology with Programmed Stimulation 
Protocols for in vivo mouse electrophysiology have been described in detail 153, 154. Investigators 
were blinded to the sample group allocation during the experiment and analysis of the experimental 
outcome. Briefly, control Ctnnb1flox/+ mice (n=6) and experimental Mlc2vCre/+; Ctnnb1flox/+ mice 
(n=6) between 2 and 4 months of age were studied. Mice were anesthetized with isoflurane, 
intubated, laid down on a heating pad to maintain core body temperature, and limb leads were 
placed subcutaneously to obtain multi-lead ECGs. An octapolar 1.7-French electrode catheter 
(CIBer mouse-EP, NuMED) was placed in the right atrium and ventricle under electrogram 
guidance through a jugular vein cutdown. A data acquisition unit (PowerLab, ADInstruments) was 
used to deliver electrical impulses at approximately twice the diastolic threshold, and to record 
surface ECGs and intracardiac electrograms. Electrograms were sampled at 2 kHz, high-pass 
filtered at 20 Hz and notch filtered at 60 Hz. To avoid aliasing, a 500 Hz low-pass filter was applied 
to the signal. Standard pacing protocols were used to assess right ventricular conduction, 
refractoriness and arrhythmia inducibility. For determination of arrhythmia susceptibility, a 
programmed pacing protocol that consists of single, double, and triple extrastimuli followed by 
burst pacing was performed on each heart. For single extrastimulus, a pacing drive train of 20 S1 
at a cycle length of 100 ms was used, followed by an S2 with a 50 ms coupling interval, which 
was reduced in 5 ms intervals until loss of ventricular capture (ventricular effective refractory 
period, VERP). For double extrastimuli, a drive train of 20 S1 at a cycle length of 100 ms was 
followed by an S2 coupled at 50 ms and an S3 coupled at 50ms. S2 and S3 were brought in by 5 
ms until reaching the VERP. For ventricular triple extrastimuli, a drive train of 20 S1 at a cycle 
length of 100 ms was followed by an S2, S2, S3, and S4 coupled at 50 ms. Similarly, S2, S3, and 
S4 were brought in by 5 ms until VERP. For burst pacing, a 2 second burst pacing at a cycle length 
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of 50 ms was used for the first burst, followed by successive bursts with a 5 ms decrement of the 
cycle length until VERP. Studies were performed and arrhythmias were noted by two independent 
investigators who were blinded to the genotype of the mice. All mice were euthanized at end of 
study. 
Surface EKG and Conscious Telemetry Recordings 
Investigators were blinded to the sample group allocation during the experiment and analysis of 
the experimental outcome. Surface EKGs were performed on conscious mice using EKG Tunnel 
(EMKA Tech), and with isoflurane, as previously described 153. For pilot telemetry studies, 
developmental Wnt LOF (Mlc2vCre/+; Ctnnb1dm/flox, n=2 females; 1 male) mice and a littermate 
control (Ctnnb1flox/+, n=1 male) were between 3-5 months of age. ETA-F10 implantable radio 
frequency transmitters for EKG (Data Sciences International Inc.) were implanted subcutaneously 
in the posterior neck of adult mice. Leads were tunneled to the anterior chest in lead II position. 
After a post-implant recovery period of one week, ambulatory heart rhythm and HR were 
monitored in caged, moving mice. Once per night, mice were injected with isoproterenol 
intraperitoneally (0.2 mg/kg in weight). Recordings were obtained continuously at 1 kHz over a 
one-week period. HR and RR intervals were calculated at baseline and following isoproterenol 
injection using a custom Matlab program.  
Histology and Immunohistochemistry 
Immunohistochemistry was performed on OCT-embedded frozen sections (Sakura 4583) with a 
combination of sarcomeric α-actinin antibody (1:100, Abcam ab9465), NaV1.5 antibody (1:100, 
Cell Signaling Technology 14421), PCM1 antibody (1:1000, Sigma HPA023370), Active β-
catenin antibody (1:50, DSHB U of Iowa) and Connexin 43 antibody (1:50, ThermoFisher 71-
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0700). Secondary antibodies included Alexa Fluor 488 (1:200, Abcam ab150077, ab150113, and 
ab150121) and Alexa Fluor 568 (1:200, Abcam ab175471). Slides were treated with TrueBlack 
Lipofuscin Autofluorescence Quencher (Biotium) and then with DAPI (Sigma 28718-90-3).     
Western Blotting 
Protein lysates were prepared from human left ventricle (LV) slices and used for immunoblotting 
as previously described155. Briefly, ventricular slices were homogenized in ice-cold 1X RIPA lysis 
buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1% Triton-X, 0.5% Sodium Deoxycholate, 
0.1% SDS) with protease inhibitor cocktail tablet (1 tablet per 50 mL lysis buffer, Roche). Samples 
were centrifuged at 13200 g for 10 minutes at 4°C. The supernatants were used for electrophoresis 
following protein analysis via BCA assay (ThermoFisher 23225). Protein fractionation was 
performed using a subcellular protein fractionation kit for tissues (ThermoFisher 87790). 
Immunoblotting was performed using anti-β-catenin (1:1000, BD Biosciences 610153), anti-
Connexin 43 (1:250, Invitrogen 71-0700), anti-NaV1.5 (1:1000, Abcam ab56240), anti-Phospho-
Connexin 43 (1:1000, Cell Signaling Technology 3511), anti-Non-phospho β-catenin (1:1000, 
Cell Signaling Technology 8814), anti-Na,K-ATPase (1:1000, Cell Signaling Technology 23565), 
anti-Lamin A/C (1:1000, Cell Signaling Technology 2032), anti-Histone H3 (1:1000, Cell 
Signaling Technology 9715), and anti-GAPDH (1:2000, Cell Signaling Technology 14C10) 
antibodies. Secondary detection was performed using HRP antibody (1:5000, abcam ab6721, 
ab205719) and Clarity Western ECL Substrate (Biorad). 
2.4 RNA Sequencing 
For adult RNA-sequencing, Wnt LOF (Mlc2vCre/+; Ctnnb1dm/flox) and littermate control 
(Ctnnb1flox/+) RV and LV were used (n=2 females; 1 male for each group). RV and LV were 
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obtained from same animals. For embryonic RNA-sequencing, Wnt GOF (αMHC-Cre; 
Ctnnb1fl(ex3)/+) and littermate control (Ctnnb1fl(ex3)/+) E12.5 embryos were used, n=2 RV and LV 
were pooled for one sample, and 6 samples of each genotype were sequenced. Illumina libraries 
were constructed by the GTAC at Washington University School of Medicine. After ribosomal 
RNA depletion, reverse-transcription with random-priming, library construction and multiplexing, 
samples were sequenced on an Illumina HiSeq 2500 using indexed libraries multiplexed at 6 
samples per lane. Single-end 50-base sequencing reads with a total target depth of >25 million 
reads were performed. Raw sequence reads were de-multiplexed, aligned to the reference sequence 
with Tophat v2.0.8 and Bowtie2 v2.1.0, and gene and exon-level abundances derived by HTSeq. 
GTAC analytical pipeline simultaneously performed a standard EdgeR and DEXSeq analysis of 
gene-level and exon-level features on the uniquely aligned, unambiguous count of reads per feature 
as determined by HTSeq using a negative-binomial test or generalized-linear negative-binomial 
model, respectively. Genes or exons were filtered to include only those that are expressed, and 
results were filtered to include only differentially expressed genes or exons. Lists of genes 
differentially regulated in the RV and LV of Wnt LOF compared to littermate control animals were 
used to generate a Venn diagram using an online resource: 
http://bioinformatics.psb.ugent.be/webtools/Venn/.  
Accession number: Data have been deposited in the NCBI GEO database: 
Wnt LOF: GSE106507 Token: qrihkmgonhyndef 





Reverse transcription-quantitative polymerase chain reaction 
Total RNA was isolated from human LV slices using Trizol (Invitrogen) and DNase treated using 
TURBO DNA-free™ Kit (Invitrogen). RNA concentrations were determined using NanoDrop 
One (ThermoFisher). First strand cDNA was synthesized using a high-capacity cDNA Reverse-
transcription kit (Applied Biosystems). Primers were designed on IDT and validated using bulk 
human or mouse cDNA. Gene expression was assayed using the PowerSYBR Green PCR 
MasterMix (Applied Biosystems) using primers listed below and quantified using the QuantStudio 
Flex 6 Real-Time PCR system (Applied Biosystems). Relative fold changes were then calculated 
using the comparative CT method, with the most stable reference genes chosen for analysis using 
NormFinder and geNorm156-158. 
Human RT-qPCR oligonucleotide sequences  
Gene Forward Reverse 
ACTC1 5' CCACCTTCCCTCATCTTTCATC 3' 5' GCAAGTCCTGGTCTGGTTTAT 3' 
GAPDH 5' GAACATCATCCCTGCCTCTAC 3' 5' CAGTGAGCTTCCCGTTCAG 3' 
ACTB1 5' GATGAGATTGGCATGGCTTTATT 3' 5' ACCTTCACCGTTCCAGTTT 3' 
SCN5A 5' AGCTGGCTGATGTGATGGTC 3' 5' CACTTGTGCCTTAGGTTGCC 3' 
GJA1 5' CAATCTCTCATGTGCGCTTCT 3' 5' GGCAACCTTGAGTTCTTCCTC 3' 
TCF7L2 5' CTGACTTCTTGTTGTTGTTGGT 3' 5' GCGTGAGTTTGGGTTTCTTT 3' 
LEF1 5' AGGAAGTGGACGTTTCGTTATC 3' 5' ACCCTCTCCACTGTAGTTACC 3' 
AXIN2 5' CAACACCAGGCGGAACGAA 3' 5' GCCCAATAAGGAGTGTAAGGACT 3' 
FGF12 5' CAGCGACTACACTCTCTTCAATC 3' 5' TCACCATTCATGGCCACATAG 3' 
 
Mouse qRT-PCR oligonucleotide sequences 
Gene Forward Primer Reverse Primer 
Scn5a 5' GAAGAAGCTGGGCTCCAGA 3' 5' CATCGAAGGCCTGCTTGGTC 3' 
Gja1 5’ ACAAGGTCCAAGCCTACTCCA 3’ 5’ CCCCAGGAGCAGGATTCTGA 3’ 
Axin2 5' CAGCCCTTGTGGTTCAAGCT 3' 5' GGTAGATTCCTGATGGCCGTAGT 3' 
Hey2 5’ CGACGTGGGGAGCGAGAACAAT 3’ 5’ GGCAAGAGCATGGGCATCAAAGTA 3’ 
Tbp 5’ GGGATTCAGGAAGACCACATAG 3’ 5’ CCTCACCAACTGTACCATCAG 3’ 






Tissue samples were processed for ChIP as described previously with a few modifications 159. 
Briefly, for each biological replicate, 4 X 107 cells from single adult LV free wall, adult RV free 
wall, or embryonic ventricles were cross-linked with 1% formaldehyde for 30 mins at room 
temperature and flash frozen and stored at -80oC until further use. Chromatin was sheared to 
approximately 500 base pairs using a Bioruptor sonicator (Diagenode, Sparta, NJ). Chromatin was 
precleared using protein G, precipitated with anti-β-catenin antibody (Cell Signaling Technology 
8814), or negative control anti-IgG antibody (Abcam ab46540). A motif search performed using 
Transfac Professional V10.2 identified a consensus Tcf/Lef binding motif with a helper site 90 
within the Hey2 Enh3 genomic region (chr10:30,717,463-30,718,805), while the Hey2 Enh2 heart 
enhancer (chr10:30,948,697-30,949,670), Hey2 Enh1 heart enhancer (chr10:30,772,887-
30,773,894), and Hey2 promoter region (640bp - 140bp upstream of TSS) did not contain a 
consensus Tcf/Lef binding motif. The Bhlh2 locus (108610745 in the 3’ UTR) was a positive 
control, and given that there are no consensus Tcf/Lef binding motifs in Scn10a proximal promoter 
(~500bp upstream of TSS), we chose this region as a negative control. For H3K27ac ChIP, the 
negative control was a gene desert region (chr15:70,649,224-70,649,887), and the positive control 
was a Gata4 peak (chr14:63,263,061-63,263,183). After reverse cross-linking, 
immunoprecipitated DNA was purified and analyzed using quantitative PCR (qPCR) and SYBR 
Green chemistry. Primer sequences for qPCR are indicated below. Fold enrichment was calculated 
as 2∧(Ctinput − Cttest) and expressed relative to the IgG negative control.  
ChIP-qPCR oligonucleotide sequences 
Gene Forward Primer Reverse Primer 
Hey2 TSS       




Enhancer 1 5’ AGTGAGATGGGAAGTCAGAGA 3’ 5’ CATGGTGCCAGGGATAACTT 3’ 
Hey2 




Enhancer 3 5' GACAGGCGAGTACATCCTATAAC 3' 5' ATTTCCCTGGATTTCCGACTC 3' 
Bhlh2D 5’ GCTAGACACGGATTTCAAGTGTATCC 3’ 5’ CATCCACTGCTGGGCAAGAG 3’ 
Scn10a 5’ GCTGCCACTCAGACAAAGGAAT 3’ 5’ GTAAAGCTATGCCCTGCACCCA 3’ 
Gene desert 
region (Neg) 
5’ GGACTAGACTCTGAGATTTTGAGG 3’ 5’ GGGCTACATCCTTAAACCTCAG 3’ 
Gata4 5’ AGGAAGGGAGGCACTCTATAG 3’ 5’ GGTCAGACTGTACAACAGCTG 3’ 
 
Computational Modeling 
Electrophysiology simulations were conducted in a 3-dimensional virtual organotypic slice model 
of human ventricular tissue (dimensions: 0.8x0.6x0.04 cm; average tetrahedral edge length = 123.3 
µm). At the cellular scale, the O’Hara Rudy dynamic (ORd) human ventricular action potential 
model (mid-myocardial variant) provided a realistic representation of membrane kinetics160. As in 
previous work161, to facilitate realistic electrophysiological behavior at the tissue scale the ORd 
version of the INa model was replaced with the ten Tusscher et al. INa formulation162. To mimic the 
experimental preparation, a uniform vector field parallel to the Y-axis of the slice (i.e., 0.6 cm 
edge) was used to represent myocardial fiber orientations. Conductivity tensor values were 
calibrated to match simulated conduction velocity with experimental observations (see Results for 
specific parameter values). All stimuli were delivered via transmembrane current injection to a 
central region on the top face of the block (strength: 120 µA/cm2; duration: 10 ms; diameter = 250 
µm). Wavefront propagation was simulated on a standard Linux workstation (Intel i7-8086K 12-
core CPU @ 4.00GHz; 64 GB RAM) by solving the monodomain equation using the finite element 
method in the CARP software package163, 164. A version of this software that is free for non-
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commercial academic use is available (https://opencarp.org/); all model and parameter files 
necessary to reproduce all simulation data in this study will be made available upon request. 
Statistical Analysis 
All data are expressed as means ± standard error of the mean (SEM). For comparison of more than 
two experimental groups, the statistical significance of observed differences in mean was evaluated 
using a one-way or two-way analysis of variance (ANOVA), followed by post-hoc Tukey's 
multiple comparison test. For comparison of two experimental groups, an equal variance Student's 
t-test was used and a two-tailed P value of <0.05 was considered statistically significant. In 
comparing correlated samples, repeated-measures ANOVA was used. In analysis of contingency 




Chapter 13: Conclusions and future directions 
In this dissertation, I employed multiple molecular and physiological techniques in both murine 
and human platforms to assay the question of whether signaling pathways, namely Wnt and GSK-
3, regulate cardiac conduction and electrophysiology. The studies here examined this hypothesis 
from molecular mechanisms, by nuclear binding of transcription factors, transcription, protein 
levels, protein localization, and posttranslational processes, to phenotypic output, as shown by in 
vivo and ex vivo electrophysiology. I attempted to tell a full story from beginning to end, while 
maintaining a level of depth that would be rigorous and scientifically novel. Due to the breadth 
and interdisciplinary nature of studies conducted, many new questions are raised for each answered. 
Therefore, in this chapter, I summarize the results that I find most interesting and highlight some 
possible future directions. 
The majority of arrhythmias are not the result of genetic mutations in ion channel genes, as these 
mutations are frequently embryonic lethal. Instead, most inherited and acquired arrhythmias arise 
from dysregulation of major signaling pathways or mutation of genes that directly or indirectly 
regulate structure or ion channel genes. Furthermore, this dysregulation is often the result of 
variants at or regulation of non-coding regulatory regions of genes, such as enhancers. In the first 
part of my thesis, I looked at the Wnt signaling pathway in cardiac development and its role in 
regulation of cardiac conduction. Although it is known that Wnt signaling is required for proper 
cardiac development, its role in cardiac electrophysiology is poorly understood. Using myocyte-
specific modulation of canonical Wnt signaling through β-catenin, which allows for the precise 
examination of Wnt-mediated transcription, I found that the pathway functions differentially in the 
right and left ventricles. Compared to control hearts, loss of canonical Wnt signaling 
embryonically resulted in 1500 genes dysregulated in the adult heart. Of these genes, only 83 were 
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mutually dysregulated in both the right and left ventricles; about 700 genes in the RV, and 700 
different genes in the LV were dysregulated in Wnt LOF hearts, including genes relevant for 
electrophysiology in both chambers. This is a novel and striking result, implying that Wnt 
signaling plays vastly different roles in the maturation of the right and left ventricular chambers, 
and loss of Wnt-mediated transcription leads to chamber-specific changes that persists to 
adulthood. To further delve into the molecular mechanism underlying this phenomenon, we used 
ChIP to assay for β-catenin binding to chromatin regions of dysregulated genes in the RV and LV. 
Specifically, we examined Hey2, a gene that has been linked to Brugada Syndrome, and found that 
there is differential β-catenin binding levels at one Hey2 enhancer region in RV and LV of wildtype 
murine hearts. This results in differential expression of the Hey2 gene in the RV and LV, which 
can be increased in the RV but not LV when β-catenin is stabilized (Wnt GOF). To answer the 
question of how differential binding of a transcriptional cofactor can occur in the RV and LV, we 
performed histone ChIP and found that early in development, the histone modifications at the Hey2 
enhancer are different in RV versus LV, which may result in distinct chromatin accessibility in the 
right versus left ventricular nuclei. A future direction for this result is to ask how many other genes 
are regulated in this manner by performing sequencing experiments to determine transcription 
factor binding, histone modifications, and other chromatin accessibility assays at promoters and 
enhancers of every gene in RV vs LV cells. The results here suggests that for one specific enhancer 
of Hey2, the mechanism of gene regulation is dependent on chromatin accessibility and binding of 
a transcriptional cofactor. However, other mechanisms involving 3D chromatin shape, nuclear 
chromatin localization, and levels of transcription factors are certain to be relevant for regulation 
of transcription for other genes. Overall, the mechanism illustrated here contribute to our 
understanding of how asymmetric development occurs, through intrinsic differences in the 
106 
 
chromatin landscape and activation of signaling pathways that thus affects cells of different 
lineages differentially.  
The consequence of Wnt loss-of-function primarily affected cardiac electrophysiology only in the 
right ventricles of adult murine hearts. Transcription of conduction-relevant genes and the encoded 
proteins were affected differentially in the right and left ventricles. This resulted in conduction 
slowing in only the RV, and increased susceptibility to arrhythmias, which affects the entire heart. 
Several inherited arrhythmias, including Brugada syndrome and arrhythmogenic cardiomyopathy 
(ACM), primarily affects the right ventricle. There are reports linking perturbation in Wnt with 
ACM, which is a complex condition that manifests both structural and electrophysiological defects. 
By using a murine model that specifically targets canonical Wnt transcription specifically in 
cardiomyocytes, I showed that Wnt LOF hearts recapitulates the conduction slowing and 
arrhythmias susceptibility seen in ACM in the absence of structural phenotypes. This may further 
delineate the role of Wnt signaling in a subset of inherited cardiac diseases that are also associated 
with arrhythmias. Finally, this study may hold implications for iPS-CM differentiation protocols, 
which currently modulates the Wnt pathway through activation followed by sequential inhibition. 
I show here that embryonic perturbation of Wnt results in differential transcriptional and 
physiological effects on the RV and LV. Current iPS-CM differentiation protocols have difficulties 
in deriving right ventricular myocytes, which hinders the development of a human platform for 
studying cardiac diseases with RV predilection. My results imply that this may be the result of the 
iPS progenitors responding to early Wnt modulation that restricts their fate to LV myocytes.      
Only recently has the identity of right versus left ventricles started becoming an area of 
investigation, and our study demonstrates contrary to the notion that RV and LV cardiomyocytes 
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are similar; embryonic perturbation of signaling pathways transcriptionally affects the ventricles 
differentially and results in consequences in the adult heart.  
In the second part of my thesis, I asked whether GSK-3 inhibition, which can activate Wnt/β-
catenin transcription, would have electrophysiological effects in the adult human heart. 
Specifically, if there are electrophysiological effects, would they be Wnt/β-catenin-mediated. 
Given that both the Wnt and GSK-3 pathways are often dysregulated in the setting of acquired 
heart diseases that are associated with arrhythmias, and that the pathways overlap in their signaling 
components, there is a need to better understand how dysregulation of these pathways in the adult 
heart can lead to disease. Furthermore, both Wnt and GSK-3 have become potential therapeutic 
targets in a multitude of cardiac and non-cardiac conditions, such as hypertrophic cardiomyopathy 
and cancer. Therefore, there is an additional need to consider cardiac safety and arrhythmias risk 
in humans before developing drugs that target these complex and ubiquitous signaling pathways. 
In order to address these questions, I used a human cardiac organotypic slice culture platform that 
allowed me to probe the acute effects of GSK-3 inhibition both at the molecular and physiological 
levels. In slices treated with SB2, a potent GSK-3 inhibitor, conduction velocity and action 
potential upstroke velocity were decreased at both 3 hours and 24 hours in culture. These results 
demonstrate that inhibition of the GSK-3 pathway in the adult heart can lead to electrical substrate 
changes that increase the risk for arrhythmogenesis. This could be particular dangerous for patients 
with preexisting arrhythmias or vulnerable electrical substrates, such as atrial fibrillation; it can be 
imagined that further modifying the ventricular electrical substrate in the setting of atrial 
fibrillation may lead to increased risk for reentrant arrhythmias. Some interesting future directions 
could be to study the chronic effects of GSK-3 inhibition or to compare the effects in heart failure 
hearts using this platform. However, the former is difficult due to the system being un-optimized 
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for extended periods of culture past 24 hours. Optimistically, the power of the platform has drawn 
many engineers to address these issues, and recent studies that have shown preserved 
transcriptome and physiology at 1 week in culture or longer. Computational modeling by our 
collaborator Dr. Patrick Boyle showed strong agreement with our experimental electrophysiology 
data. The model used was derived independently of the present experimental data, but showed near 
perfect prediction of complex electrophysiological relationships, validating both the model and the 
platform as robust methods. Additionally, the model predicted a level of sodium conductance 
decrease that matches with the NaV1.5 protein decrease I observed experimentally. However, the 
model also predicted a parallel decrease in tissue conductivity to yield the magnitude of CV 
decrease observed. Although I tried to address this by looking at connexins, I wasn’t able to find 
differences between control and SB2-treated slices. Therefore, it would be interesting to determine 
whether other posttranslational or pretranscriptional processes could account for decreased tissue 
conductivity or even greater decreased sodium channel conductance.  
An interesting molecular result from the GSK-3 inhibition studies that ties in to Wnt signaling is 
the increase of β-catenin in the nuclei of the slices treated with the GSK-3 inhibitor. While it is not 
surprising that inhibition of GSK-3 can lead to accumulation of β-catenin, which can eventually 
translocate to the nucleus, the observed increase of β-catenin in the nucleus unexpectedly did not 
confer transcriptional changes. Therefore, although I’ve shown that canonical Wnt/β-catenin 
signaling transcriptionally regulates electrophysiology genes, it is unlikely that this is the 
mechanism for the observed decrease in CV of the acute GSK-3 inhibition studies in human 
cardiac slices. Elucidating the exact mechanism would require generating a proteomic map and 
assaying whether SB2 modulate interactions between ion channel proteins and other proteins. 
Another approach would be to exhaustively look for markers for pretranslation and posttranslation 
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of the transcripts and proteins of ion channel genes. Another potentially interesting finding is that 
β-catenin is present at baseline in the nuclei of myocardial cells, which to my knowledge is novel 
in the adult heart. It is cardinal in the field that Wnt signaling is quiescent in the adult heart at 
baseline, and that β-catenin levels are regulated to a low level in the cytoplasm, which 
consequently results in little β-catenin translocation to the nuclei to activate Wnt signaling target 
genes. Here, I show robustly by Western blot and immunofluorescence that β-catenin exists at a 
moderate level in myocyte nuclei, and that acute GSK-3 inhibition increases these levels. 
Additionally, Western blot for β-catenin shows bands of multiple sizes in the chromatin-bound 
fraction but only one size in other subcellular fractions; whether these different β-catenin isoforms 
have significance in gene regulation remains an area of future investigation. Therefore, a 
potentially impactful direction for understanding Wnt signaling in the adult heart is to determine 
the role of cardiomyocyte nuclear β-catenin. There is only one recent study that demonstrate β-
catenin nuclear localization in the adult heart at baseline, and the authors propose that β-catenin 
sits in a repressive complex at baseline and cannot activate Wnt target genes without nuclear 
landscape changes brought by pathologic stimuli. These results are consistent with my findings 
here, but the question remains whether nuclear β-catenin is required for homeostatic processes, 
such as repression of other transcriptional pathways or activation of non-Wnt target genes. To 
determine whether baseline nuclear β-catenin is involved in homeostatic transcription, I can use 
the transcriptionally incompetent β-catenin (Wnt LOF) here and perform RNA sequencing in an 
adult inducible model. Even if cardiac electrophysiology is unaffected, this study could provide 
insight into Wnt biology in the adult heart.    
Overall, I believe that my thesis work have increased our understanding of the Wnt signaling 
pathway in regulation of cardiac electrophysiology in both development and adulthood, and may 
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hold implications for basic cardiac biology and physiology as well as the development of 
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